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ABSTRACT
Parkinson s disease (PD) is a neurodegenerative disorder characterized by
dopaminergic cell death in the substantia nigra pars compacta (SNc) and
dopamine (DA) depletion in the striatum. Current pharmacological treatments
are aimed at the replacement of striatal DA via the administration of levodopa.
While this therapy is beneficial initially, long-term treatment is associated with
significant side effects, and disease progression contiues. The present
experiments investigate neuroprotective and neurotransplantation strategies as
alternatives to pallative pharmacologic treatments;
The optimal therapeutic approach to neurodegenerative diseases would
be to protect against cell death and prevent disease progression. PD is well-
suited for such neuroprotective strategies as primarily one cell population is
affected in this disorder. Neurotrophic factors (NTFs) have been identified
which support dopaminergic neuronal survival in vitro. In the present studies,
the neuroprotective effects of the neurotrophin brain-derived neurotrophic factor
(BDNF) have been evaluated in a 1-methyl- phenylpyridinium (MPP+) model
of substantia nigra (SN) degeneration. BDNF-secreting fibroblasts were
implanted dorsal to the SN prior to the infusion of the mitochondrial complex I
inibitor MPP+. Subsequent histological analysis demonstrated that BDNF 
able to attenuate MPP+ induced dopaminergic cell loss in the SNc. Moreover
neurochemical evaluation demonstrated that BDNF is able to enhance DA levels
in the remaining SN neurons in this same paradigm.
The cause of cell death in neurodegenerative diseases likely involves the
interaction of mitochondrial impairment, excitotoxicity, and oxidative stress. In
order to evaluate the mechanism of NTF-mediated protection, the abilty of nerve
growth factor (NGF) to attenuate the production of the oxidant peroxynitrite was
evaluated in a model of mitochondrial impairment. NGF was found to decrease
the production of 3-nitrotyrosine, the product of peroxynitrite mediated tyrosine
nitration. Thus, NTF-mediated neuroprotection may act in part by decreasing
reactive oxygen species and oxidative stress.
At present, neuroprotective therapie ot clinically available. An
alternate therapeutic approach to PD is the replacement of striatal DA and
reconstruction of synaptic circuitry via the intrastriatal transplantation of fetal
dopaminergic neurons. Current transplantation protocols using human fetal
tissue are constrained by limited tissue availabilty. In order to investigate an
alternate cell source for the treatment of PD, fetal porcine dopaminergic neurons
were implanted into the DA depleted striatum of 6-0HDA lesioned rats.
Amphetamine-induced rotational recovery was monitored, and graft survival
was evaluated 19 weeks after grafting. In immunosuppressed rats, porcine
dopaminergic neurons were found to attenuate rotational deficits and
extensively reinervate the host striatum.
The neuroprotective effects of BDNF suggest that NTFs may be important
mediators of dopaminergic neuronal survival and fuction in the adult brain.
However, several conditions including appropriate dosage and delivery need to
be determined before clinical applications may be achieved. As an alternative to
neuroprotection, neurotransplantation not only restores striatal DA but also
reconstructs the synaptic circuitry of the basal ganglia. The finding that porcine
dopaminergic neurons survive with in adult host brain
, reinervate the DA
depleted striatum, and mediate fuctional recovery suggests that porcine DA
neurons may serve as an alternate cell source for transplantation in PD.
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CHAPTER I
INTRODUCTION
Parkinson s disease
Clinicopathological features. Parkinson s disease (PD) is a progressive
neurodegenerative disorder characterized by bradykinesia, rigidity, restig
tremor, and postural instabilty (Hoehn and Yahr, 1967). Parkinsonian patients
characteristically have a stooped posture, walk with a shufflng gait, and show
reduced facial expression. In addition to the classical clinical symptomatology 
there are pathognomonic neuropathologic changes defined by diffuse
distribution of cytoplasmic Lewy bodies and cell loss within the substantia nigra
(SN) (Feamley and Lees, 1994; Marsden, 1982a). In addition, pathologic features
may also be observed in the locus coeruleus, dorsal motor vagal nucleus, nucleus
basalis of Meynert, and cortex. Dysfuction of the nigrostriatal system
associated with dopaminergic cell loss in the substantia nigra pars compacta
(SNc) and the secondary depletion of striatal dopamine (DA) levels likely'
account for the motor deficits of PD (Marsden, 1982b). The degree of neuronal
loss in the SNc is paralleled by the reduction of striatal DA (Berneimer et al.
1973), with levels in the putamen more severely depleted than the caudate (Kish
et al. , 1988; Nyberg et al., 1983). Moreover, there is a rostrocaudal gradient of DA
depletion in which the caudal putamen is the most affected (Kish et al., 1988).
As a consequence of the striatal DA depletion, presynaptic and
postsynaptic compensatory changes occur in the PD brain. DA turnover in the
remainng DA neurons increases (Bernheimer et al., 1973) and receptor
supersensitivity develops (Lee et al., 1978). Thus, while the loss of striatal DA
correlates with the severity of clinical disabilty in PD, clinical manifestations are
not apparent until 80-85% of nigral neurons have degenerated and striatal 
levels are depleted by 80% (Marsden, 1982a). Since pathologic changes precede
the manifestation of clinical symptoms, it is of interest to develop strategies to
protect remaining DA neurons during this subclinical stage in order to prevent
the progression of cell loss and onset of clinical dysfuction.
idemiolo . Most cases of parkinsonism are due to degenerative
processes and are classified as idiopathic PD. However, parkinsonian signs may
also be associated with multisystem atrophy, cerebrovascular disease
tencephalitic parkinsonism, toxin ingestion (e.g., manganese, see MPTP
below) or drug intoxication (e.g., neuroleptics). Parkinsonism is rarely
attributable to tumor or trauma Gellinger, 1986).
Estimates for the prevalence of PD range from approximately 100 - 300
cases per 100, 000 individuals (0.1%- 3%); and this rate increases with increasing
age (Marttila and Rie, 1981; Rajput, 1992). Males and females show similar
prevalence rates, and whites are more commonly affected than are other races
(Tanner, 1992). While it is unclear to what extent environmental factors may
cause PD, exposure to well water, rural environments, farming, and herbicides
has been associated with an increased risk for developing PD (see Tanner
, 1992
for review). In addition, cigarette smoking had been found to be inversely
, correlated with PD, suggesting a possible preventative effect (Baumann et al.
1980; Godwin-Austen et al. , 1982; Marttila and Rie, 1980). No relationship,
however, has been found between the degree of smoking and the severity of PD
(Golbe et al. ' 1986). Interestingly, it has recently been reported that monoamine
oxidase-B (MAO-B) levels are reduced in the brains of smokers, and it has been
suggested that decreased production of reactive oxygen species due to lower
levels of MAO may account for the suggested neuroprotective effect (Fowler et
al. 1996).
Etiolo and Patho enesis. The cause of DA neuron loss in the SNcin
idiopathic PD is not known. Based on low concordance rates amongst
monozygotic twin, a significant mendelian genetic component to the etiology of
idiopathic PD was initially considered unlikely(Duvoisin, 1986; Marsden, 1987;
Marttila et al., 1988; Ward et al., 1983). However, reevaluation of the twin studies
(Golbe, 1990) as well as assessment of additional families (Maraganore et al.
1991; Vieregge et al., 1992) suggest there is an increased familal tendency for PD
with an approximate 3.5-fold greater risk for PD in first degree relatives of an
affected individual compared to relatives of control subjects (Payami et al., 1994).
Furthermore, positron emission tomography (PET) scan studies have revealed a '
significant decrease in fluorodopa uptake in asymptomatic co-twins, with a
concordance rate of 45% in monozygotic twins (Burn et al. , 1992).
There are also some kindreds which display autosomal dominant
parkinsonism (e.g., Golbe et al., 1990; Markopoulou et al., 1995; Waters and
Miler, 1994; Wszolek et al., 1995). Yet, in some of these cases, earlier onset
(Markopoulou et al., 1995; Waters and Miler, 1994) and a more aggressive
clinical course (Golbe et al. ' 1990) as well as atyical pathology have been
observed (Waters and Miler, 1994). Genetic analyses in familes with autosomal
dominant parkinsonism have failed thus far to identify a genetic cause for 
(Bandmann et al., 1995; Gasser et al. , 1994; Parboosingh et al. , 1995), and no
association with a CAG trinucleotide repeat has been found (Carrero-Valenzuela
et al., 1995) as has been shown for other neurodegenerative disorders such as
Huntington s disease (HD) (The Huntington s Disease Collaborative Research
Group, 1993).
The development of parkinsonism following the administration of the
mitochondrial complex I inhibitor 1-methyl- phenyl- tetrahydropyridine
(MPTP, see below) (Langston et al. , 1983) suggests that a structurally similar
environmental or endogenous agent may cause PD by a similar mechanism of
neurotoxicity. However, no such environmental risk factor has been'
identified(Tanner 1989). The precise role of heredity and environment remains
unclear, but it has been suggested PD may be due to an interplay of toxin
exposure, genetic susceptibilty, and aging. Cell loss due to a genetic
susceptibilty to a toxic insult, in combination with the progressive loss of
nigrostriatal neurons associated with normal aging (McGeer et al., 1977;
Scherman et al., 1989), may surpass a threshold of DA cell loss beyond which
symptomatic PD ensues (Caine and Langston, 1983).
Clinical abnormalities and post-mortem findings in PD patients have led
to various hypotheses regarding the mechanisms for progressive cell loss in PD.
Several lines of evidence suggest that oxidative stress contributes to the
pathogenesis of PD. Post-mortem analyses have demonstrated increased lipid
peroxidation in the SN of PD brains suggesting either an excess production of
neurotoxic free radicals or a failure of the normal protective mechanisms(Dexter
et aI., 1986; Dexter et al. , 1989; Dexter et al., 1994). Several detoxifying systems
have been found to be altered in the PD brain including decreased activities of
catalase, peroxidase (Ambani et al., 1975), and glutathione peroxidase (Kish et al.
1985) as well as decreased levels of reduced glutathione (Perry et al. , 1982; Sian et
al., 1994a). The decreased levels of glutathione are likely due to in part to
increased breakdown as the degradative enzyme y-glutamyltranspeptidase ' has
been found to be elevated in parkinsonian brains (Sian et al. , 1994b). In addition
elevated iron levels are found in the SN of PD patients (Dexter et al., 1987). Since
iron can generate cytotoxic free radicals, high levels of iron may contribute to
oxidative stress and lipid peroxidation. The dopaminergic neurons of the SN
may be particularly vuInerable to oxidative stress due to the metabolism of DA
(Olanow, 1990). DA is oxidized to hydrogen peroxide via MAO-B. In the
presence of iron, hydrogen peroxide is metabolized to reactive hydroxyl radicals
via the Fenton reaction. Thus, the elevated iron levels found in the PD brain
combined with impaired antioxidant mechanisms may exacerbate ongoing free
radical generation and oxidative damage (Fahn and Cohen, 1992; Olanow, 1990).
Further post-mortem as well as clinical studies have demonstrated mitochondrial'
abnormalities in PD patients. Similar to the inbition of mitochondrial fuction
produced by MPTP, defects have been found in complex I of the electron
transport chain in SN (Schapira et al., 1990; Schapira et aI., 1989), platelet(Haas 
al., 1995; Parker et al., 1989), and muscle(Shoffner et al. , 1991) mitochondria
preparations from PD subjects. Such fidings suggest PD may be due to an
inerited mitochondrial defect. However, no known mitochondrial genetic
defect or deletion has been detected (Shoffner et al.
, 1991). The significance of
these findings with respect to the etiology ofPD remains to be determined as it is
unclear if these abnormalities cause neuronal degeneration or are a consequence
thereof.
Functional or anization of the basal lia and the role of do amine.
The clinical manifestations of PD can be understood by examining the role of DA
in the basal ganglia (Figure 1). The basal ganglia motor circuit is comprised of
two parallel pathways which process cortical glutamatergic input (Albin et aI.
1989; Alexander and Crutcher, 1990; DeLong, 1990). The direct pathway refers to
striatal GABAergic and substance P inibitory fibers which project to the internal
segment of the globus palldus (GPi) and substantia nigra pars reticulata (SNr).
In turn, GABAergic fibers from the SNr and GPi project to the thalamus, which
sends excitatory fibers to the cortex. The indirect pathway projects to the GPi
and SNr via a more circuitous route: Striatal GABAergic and enkephalin
containing fibers project from the striatum to the external segment of the globus
palld us (GPe), and GABAergic fibers from the GPe project to the subthalamic
nucleus (STN). The STN sends excitatory fibers to the GPi and SNr as well as to
the GPe and cortex. Thus, activation of the direct pathway facilitates
thalamocortical transmission whereas activation of the indirect pathway inhibits
such activity. The nigrostriatal DA neurons serve to modulate this circuit by
inibiting the indirect and facilitating the direct pathway. These effects are likely
mediated by the differential expression of DA receptor subtypes on striatal
projection neurons. D1 receptors are expressed by neUrons of the direct
pathway, whereas D2 receptors are expressed by neurons of the indirect pathway
(Robertson, 1992). Thus, in PD, where DA levels are depleted, the indirect
Figure 1. Basal ganglia circuitry and the role of DA. DA normally facilitates the
direct pathway and inibits the indirect pathway. In PD, the direct pathway is
inibited whereas the indirect pathway is active due to the loss of DA.
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pathway is active whereas the direct pathway is inibited, thereby producing
thalamocortical inhibition (DeLong, 1990).
Pharmacolo ical treatment strate ies. The mainstay therapy for PD
remains pharmacological replacement of DA via the oral administration of
levodopa (L-dopa), the precursor to DA (Caine, 1993). L-dopa is absorbed in the
proximal intestine, crosses the blood-brain-barrier (BBB), and is converted toDA
via aromatic L-amino acid decarboxylase (dopa decarboxylase) contained in the
nerve terminals of dopaminergic as well as non-dopaminergic neurons of the
striatum (Hefti and Melamed, 1980; Hornykiewicz, 1974). As most L-dopa is
metabolized prior to reaching the brain, co-administration of a peripheral dopa
decarboxylase inibitor such as carbidopa improves the efficacy and decreases
the peripheral side effects of this drug (Cotzias et al. , 1969; Koller and Hubble
1990). L-dopa is highly effective in reducing bradykinesia and rigidity, yet
tremor and postural instabilty are less improved (see Koller and Hubble, 1990
for review). While L-dopa therapy offers dramatic clinical improvement, long-
term therapy is associated with significant side-effects including dyskinesias and
psychosis as well as altered drug responses characterized as "end-of-dose
deterioration" or "on-off phenomena" (Fah, 1974; Marsden, 1982a; Marsden and'
Parkes, 1976). The precise physiologic processes underlying these effects are
unclear, but they are thought to be associated with the fluctuations in L-dopa
levels as well as DA receptor alterations (Chase et al.
, 1993). Indeed, motor
fluctuations decline during contiuous steady-state infusions of L-dopa
suggesting that the intermittent dosing of L-dopa contributes to the observed
motor abnormalities (Mouradian et al., 1989). As these motor fluctuations may
be associated with the duration of L-dopa therapy, treatment with L-dopa is
usually delayed until fuction is impaired (Melamed , 1986; Yahr, 1977).
Moreover, it has been hypothesized that L-dopa itself may be deleterious to
dopaminergic neurons. The metabolism of DA can generate free radicals
(Olanow, 1990), and DA has been shown to be toxic for dopaminergic neurons in
culture (Michel and Hefti, 1990). Furthermore, increased DA turnover is
associated with the generation of hydrogen peroxide (Spina and Cohen, 1989),
suggesting that L-dopa administration to the PD brain may similarly cause
oxidative stress (Olanow, 1990). Indeed, L-dopa treatment reduces brain
mitochondrial complex I activity in vitro and in vivo (Przedborski et aI. , 1993)
In additon to L-dopa, direct DA agonists (e.g., bromocriptine and
pergolide) or anticholinergic drugs, which counter the acetylcholine-
imbalance, are useful alternatives or adjuncts to L-dopa therapy (Caine, 1993).
Recent treatment strategies have also included the initiation of the MAO-
inhibitor deprenyl (selegilne) soon after the onset of parkinsonian signs (Clough
1991). The rationale for deprenyl use in PD is based on the experimental finding
that MPTP-induced parkinsonism in animal models can be prevented by
inibiting MAO-B (Heikkila et al., 1984b; Langston et al., 1984). Furthermore, as
DA metabolism is associated with the generation of free radicals via the Fenton
reaction, inhibiton of MAO-B catalyzed DA metabolism may decrease oxidative
stress in the SN (Olanow, 1990). Initial clinical studies indicated that deprenyl
administration delays the onset of symptoms requiring L-dopa therapy,
suggesting this agent may retard disease progression (Parkinson Study Group,
1989; Tetrud and Langston, 1989). More recent follow-up studies, however, have
concluded that the beneficial effects of deprenyl are likely symptomatic, due
merely to attenuation of symptoms attributable to elevated levels of DA rather
than to neuroprotection (Parkinson Study Group, 1993; Parkinson Study Group,
1996b; Schulzer et al. , 1992). Additionally, prior treatment with deprenyl has
been shown to hav no effect on the development of L-dopa associated
complications (Parkinson Study Group, 1996a). Parallel studies evaluating the
abilty of the anti-oxidanUocopherol, the active component of vitamin E, to delay
the need for L-dopa treatment have failed to demonstrate any benefit (Parkinson
Study Group, 1993; Parkison Study Group, 1996a; Parkinson Study Group,
1996b ).
While pharmacological replacement therapy with L-dopa initially
provides significant symptomatic relief, decreased effectiveness and adverse
effects are associated with long-term treatment (Marsden, 1982a). The limitations
of present pharmacological treatments are clear and indicate the need for.
alternative DA replacement and neuroprotective therapies.
Sur ical treatment strate ies.
Functional neurosurgery. Historically, the treatment for PD involved
surgicallesioning of the corticospinal tracts and subsequently the stereotactic
lesioning of the extrapyramidal motor system, specifically the thalamus
(thalamotomy) or palldum (palldotomy) (see Goetz et al. , 1993; Hauser et al.
1995 for review). With the advent of pharmacological therapies such as L-dopa
surgical treatment declined. However, the untoward effects of long-term L-dopa
therapy, coupled with a greater understanding of neuronal circuitry of the basal
ganglia and the advances of stereotactic neurosurgery, have resulted in a
resurgence of surgical approaches for the treatment of PD.
The rationale for lesioning is to interrupt the basal ganglia neuronal
circuitry, thereby preventing the activation of the indirect pathway and
reestablishing the activity of the direct pathway which are altered in the
parkinsonian brain due to the DA deficiency. Thalamotomy has been shown to
be of benefit to patients with refractory tremor (Tasker, 1990). Rigidity may also
be improved by this procedure, yet bradykinesia is not affected. Similarly, high
frequency electrical stimulation in the thalamus is also associated with a
reduction in tremor, and this approach permits bilateral treatment (Benabid et aI.
1991). Lesions of the posteroventral palldum have been reported to improve
tremor, rigidity, and bradykinesia as well as L-dopa associated dyskinesias
(Laitinen, 1995; Laitinen et al., 1992). Possible complications associated with
thalamotomy include transient paresis, cognitive disorders, parasthesia
dysarthria, and gait disturbances (Tasker, 1990), whereas the primary
complication associated with palldotomy is visual field defects due to the
proximity of the lesion site to the optic tract (Laitinen et aI., 1992). While the
present surgical results are encouraging, it remains to be determined if the
beneficial effects are long-lasting and what long-term sequelae may be associated
with ablative lesioning of the brain.
Neurotransplantation. An alternative to pharmacologic replacement
therapy is physiologic replacement of DA by transplanting DA-releasing cells.
Early clinical transplantation studies involved the implantation of catecholamine-
producing cells from the adrenal medulla into the DA-depleted striatum of PD
patients (Goetz et al., 1989; Lindvall et al., 1987; Madrazo et al. , 1987; see Freed et
al., 1990b for review). While the aim of these studies was to provide an
autologous cell source of DA production, results were highly variable and of no
sustained therapeutic benefit. Due to poor graft survival and the high rates of
morbidity and mortality associated with this approach, adrenal medullary
transplantation has been abandoned(Ahlskog, 1993; Goetz et aI. , 1991).
Based on transplantation studies conducted in rodent and primate models
of PD (see below), clinical trials were initiated to evaluate the efficacy of
intrastriatal transplantation of human fetal ventral mesencephalon (VM) cell
suspensions to patients with PD. Initial studies in two patients with idiopathic
PD showed only marginal clinical effects (Lindvall et aI. , 1990b; Lindvall et aI.
1989). Using a modified protocol with d reased tissue storage time and a
thier implantatiori\ annula, encouraging results were found with the
subsequent two idiopathic,PD cases(Lindvall et aI., 1990a; Lindvall et al. , 1992;
Sawle et al., 1992). Unilateral grafts of fetal human VM into the putamen
decreased rigidity and bradykinesia, predominantly on the side contralateral to
the grafts, and also decreased the number of daily "off' periods and time spent
off" (Lindvall et al., 1990a; Lindvall et al., 1992). Clinical improvement was
apparent at approximately 6-12 weeks post transplantation, and the degree of
recovery correlated with graft survival and fuction as evaluated by 18F-
fluorodopa uptake using PET at one year post-transplantation (Lindvall et al.
1990a; Lindvall et al., 1992; Sawle et al., 1992). In a follow-up study, long-term
graft survival was assessed in these two patients at three years post-
transplantation (Lindvall et al., 1994). Both patients showed near normal 18F-
fluorodopa uptake in the grafted regions. In one patient, 18F-fluorodopa uptake
by the graft remained unchanged from that measured one year post-operative
while nongrafted striatal sites showed decreased uptake indicative of progressive
degeneration associated with the underlying disease process. The other patient
showed a continued increase in uptake and was able to discontinue L-dopa
medication. Transplantation of two additional patients with idiopathic PD using
an identical protocol has shown a similar course of clinical improvement as well
as positive PET scan results (Peschanski et al., 1994). Furthermore, bilateral cell
suspension grafts in the caudate and putamen of two patients with MPTP-
induced parkisonism have produced marked clinical improvement and a
corresponding increase in striatal uptake of fluorodopa (Widner et aI., 1992).
Additonal studies have been undertaken implanting solid pieces of tissue
rather than dissociated cell suspensions, into the striatum of PD patients (Freed
et aI. , 1992; Freed et al., 1990a; Freeman et aI., 1995; Kordower et al., 1995).
Sustained clinical improvement accompanied by increased fluorodopa uptake
has been reported up to 46 months following transplantation in one patient and
variable degrees ofimprovement have been observed in other patients of this
series (Freed et al., 1992). Likewise, in another series of four patients receiving
bilateral transplantation of solid tissue into the putamen, a significant degree of
recovery and a parallel increase in fluorodopa uptake was apparent at 6 months
after transplant (Freeman et al., 1995). A single patient from this group died 18
months after grafting due to a pulmonary embolus, permitting the
neuropathological analysis of the graft (Kordower et al., 1995). Ths patient
showed fuctional recovery and a progressive increase in fluorodopa uptake
and histological analysis revealed surviving grafts which were well integrated
with the host striatum. Extensive tyrosine hydroxylase (TH) neuronal survival
and fiber outgrowth were apparent indicating that grafted fetal cells can survive
long-term in the parkinsonian brain and reduce symptoms.
Results thus far have demonstrated the efficacy and potential utilty of
transplantation as a therapeutic modality for the treatment of PD. However
several variables including cell preparation and graft location as well as number
of cells need to be refined and optimized before neuronal transplantation can be
viewed as a therapeutic alternative for PD patients. Moreover; since
transplantation does not halt the progressive degeneration of PD, and since this
progression may counteract the graft-induced recovery, protective therapies
remain of interest.
Animal models of Parkinson s disease
The development of animal models of PD have faciltated the
investigation of neurotransplantation and neuroprotection of dopaminergic
neurons. In addition, these models have contributed to the understanding of
possible etiologies of parkinsonism. While no animal model fully parallels the
progressive neuronal death seen in PD, the administration of toxins produces
useful models of dopaminergic neuronal degeneration. The models most
commonly employed involve the administration of the neurotoxins 6-
hydroxydopamine (6-0HDA) or MPTP.
dro amine. Intracerebral injection of the neurotoxin 6-0HDA
results in selective uptake by catecholamine membrane transporters and the
irreversible destruction of dopaminergic and noradrenergic neurons (Ungerstedt,
1968). The precise mechanism for this neurotoxicity remains unclear but likely
involves the formation of H202 and free radicals by auto-oxidation or the
formation of products which act as alkylating agents (Cohen and Heikkila, 1974;
Heikkila and Cohen, 1971; see Jonsson, 1980 for review).
Unilaterallesioning of the nigrostriatal pathway with 6-0HDA provides a
useful behavioral paradigm for the study of PD, and in particular the extent of
dopaminergic reinnervation following transplantation. In this lesion model,
motor asymmetry is apparent due to striatal DA imbalance (Ungerstedt, 1968).
Administration of amphetamine causes DA release from the intact nigrostriatal
system and results in an excess of DA in the intact striatum relative to the
lesioned side. As a consequence, unilaterally lesioned rats administered
amphetamine wil rotate toward the lesioned side (ipsilateral rotation) thereby
providing a quantifiable measure of striatal DAinervation (Ungerstedt, 1971c;
Ungerstedt and Arbuthnott, 1970). Rats which rotate at least 7 turns per minute
have been found to have 97-99% striatal DA depletion (Schmidt et al. , 1983;
Schmidt et al., 1982). In addition, 6-0HDA induced striatal denervation is
associated with receptor supersensitivity (Ungerstedt, 1971b). Administration of
the DA receptor agonist apomorphine thus results in greater activation of the
lesioned side relative to the intact striatum and consequently rotation away from
the lesioned side (contralateral rotation) (Marshall and Ungerstedt
, 1977;
Ungerstedt 1971b). Furthermore, this lesion model produces sensorimotor and
paw-reaching deficits in rats (Ljungberg and Ungerstedt, 1976; Whishaw et al.
1986). Bilateral injections of 6-0HDA produce akinesia as well as adipsia and
aphagia thus precluding the use of the bilateral lesion model for most
transplantation studies (Ungerstedt, 1971a).
The behavioral deficits associated with unilateral 6-0HDA lesions and the
improvement following neuronal transplantation demonstrate the utilty of this
model for evaluating striatal inervation and functional recovery associated with
neuronal transplantation (see below). However, while the 6-0HDA lesion model'
parallels the neurochemical depletion characteristic of PD, it does not lend itself
to studies on the etiology of PD as 6-0HDA is highly toxic and acts by an
incompletely understood mechanism.
Meth hen 6-tetrah dro ridine MPTP . MPTP is a
meperidine analog which produces irreversible parkinonian symptoms in
humans (Langston et al., 1983) and has been used extensively to produce
experimental models of PD in animals (Burns et aI. , 1983; Heikkila et aI. , 1984a).
MPTP is converted to 1-methyl- phenylpyridinium (MPP+), the active
metabolite which mediates neurotoxicity, in a reaction catalyzed by MAO-
Inibition of this enzyme prevents both the conversion of MPTP to MPP+ and
hence the neurotoxicity associated with MPTP administration (Heikkila et al.
1984b; Langston et al. , 1984). The conversion of MPTP to MPP+ is localized to
serotonergic neurons and astrocytes, paralleling the distribution of MAO-B in
brain (Levitt et al., 1982). MPTP administration results in loss of DA cells in the
SNc and depletion of DA and its metabolites in the neostriatum (Burns et al.
1983; Heikkila et aI., 1984a; Langston et al., 1983). In addition, serotonergic and
noradrenergic neurons as well as glia may be affected(Burns et al. , 1983; Heikkila
et aI. , 1985; Ter Horst et al. , 1992).
The pattern of neurotoxicity produced by MPTP is accounted for by its
mechanism of action. MPTP preferentially binds to sites in the striatum, SN, and
",."
locus coeruleus where it is converted to MPP+ by MAO-B Gavitch et al. , 1984).
MPP+ is subsequently taken up by catecholaminergic transporters at
noradrenergic and DA nerve terminals Gavitch et al., 1985). As rats lack MAO-
in the nigrostriatal pathway, the active metabolite MPP+ must be administered
intracranially in order to achieve dopaminergic neuronal loss modelling PD. In
the striatum, MPP+ is retrogradely transported to the SNc thus accounting for
the neuronal loss in the SNc and depletion of striatal DA (Campbell et al., 1990;
Herkenham et al. , 1991). The neurotoxicity of MPP+ is associated with the
inibition of mitochondrial oxidative phosphorylation (Nicklas et aL, 1985) at
complex-I of the electron transport chain (Nicklas et aI., 1987). As a consequence,
there is decreased ATP production (Chan et al., 1991). It has been suggested that
this loss of ATP may result in excitotoxic cell death as decreased ATP is
associated with membrane depolarization, release of magnesium blockade of the
N-methyl-D-aspartate (NMDA) receptor, and subsequent receptor activation and
excitotoxicity (Storey et al., 1992). The role for NMDA-receptor mediated
excitotoxicity in the mechanism of MPP+ neurotoxicity is supported by the
findings that inhibition of glutamatergic input by an antagonist or decortication
is able to prevent MPP+ induced nigral degeneration (Srivastava et al., 1993).
. The finding that the neurochemical, anatomical, and behavioral
abnormalities of MPTP-induced parkisonism resemble idiopathic PD suggests
there may be a common underlying mechanism of neuronal degeneration. This
feature demonstrates the utilty of the MPTP model in developing experimental
strategies to protect against neuronal degeneration in PD.
Neurotrophic factors
Mechanisms of cellular in and neurotro hic factor interventions. 
The pathogenesi of neurodegenerative diseases is likely mediated by impaired
cellular energy metabolism coupled with oxidative stress and excitotoxicity
(Albin and Greenamyre, 1992; Beal, 1992; Beal, 1995). Excitotoxic neuronal death
is induced by glutamate receptor activation which results in calcium influx as
well as activation of an enzymatic cascade which produces free radicals and
further calcium overload (Figure 2). As a consequence of the increased
intracellular calcium levels, cellular pro teases such as calpain I and
phospholipases are activated resulting in the degradation of structural proteins
and loss of cell membrane integrity. Furthermore, oxygen radicals are generated
due to the release and metabolism of arachadonic acid as well as the conversion
of xanthine dehydrogenase to xanthine oxidase (see Choi, 1988; Choi, 1992 for
review). Nitric oxide synthase (NOS) is also activated in response to increased
intracellular calcium (Garthwaite et al., 1988), and inhibition of NOS attenuates
NMDA-induced neurotoxicity, suggesting a role for nitric oxide in glutamate
toxicity (Dawson et al., 1991c). Abnormal glutamate receptor activation alone
may account for some of the neuronal death seen in neurodegenerative diseases.
It is likely, however, that an interaction of cellular metabolic stress and oxidative
damage can result in secondary excitotoxic cell death (see Beal, 1995 for review).
Neurotrophic factors (NTFs) are able to protect neurons against a variety
of cellular insults indicating their potential therapeutic value for the treatment of
neurodegenerative disorders (Mattson et al., 1993). Among the mechanisms
, Figure 2. Mechanisms of cellular injury and neurotrophic factor protection.
Neuronal death in degenerative diseases is mediated by excitotoxicity and
metabolic dysfunction resulting in loss of calcium homeostasis and production of
free radicals. Glutamate receptor activation results in calcium influx which is
inadequately buffered when coupled with mitochondrial impairment (aging,
MPP+ NP). As a consequence, intracellular calcium levels rise and cause a
cascade of enzyme activation and free radical production. Neurotrophic factors
may protect against neurodegeneration by maintaining intracellular calcium or
by increasing the activity of free radical scavengers such as catalase, superoxide
dismutase (SOD), and glutathione reductase. (From Galpern et aI., in press;
modified from Beal, 1995, with permission)
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underlying NTF protection are the maintenance of calcium homeostasis as well
as the reduction in levels of free radicals by increasing antioxidant enzyme
activities (Cheng and Mattson, 1991; Mattson et al., 1995). By decreasing cellular
oxidative stress or by interfering in the cascade to cell death, NTFs may reduce
neuronal vuInerabilty and protect against ensuing neurodegenerative processes.
Role of neurotro hic factors. NTFs are important determinants of
neuronal development and organization, affecting innervation of target tissue as
well as survival of neurons (Purves; 1986). Classically, NTFs are secreted during
specific developmental stages by target tissues in limited quantities (Bar de, 1988).
While it was originally thought that different neuronal populations were each
responsive to only a single NTF, there is overlap and redundancy whereby a
single NTF may affect more than one cell type and a specific cell type may
respond to several NTFs (Korsching, 1993). Moreover, actions of NTFs are
associated not only with retrograde transport from the target tissue but also
autocrine and paracrine mechanisms (Kokaia et al. , 1993; Miranda et al. , 1993).
Similarly, NTF expression in the adult brain suggests various mechanisms of
action in relation to the observed selective neuronal trophism. NTFs are
important for neuronal maintenance in the adult brain, and insufficiency of such
trophic support due to decreased NTF supply or impaired target cell response
may account for some of the cell death in neurodegenerative diseases (Appel
1981; Hefti, 1983).
Classes of neurotro hic factors and re ional ex ression.
Neurotrophins. Nerve growth factor (NGF) (Levi-Montalcini, 1987), brain-
derived neurotrophic factor (BDNF) (Barde et al. ' 1982; Leibrock et aI. 1989),
neurotrophin-3 (NT-3) (Ernfors et al., 1990; Hohn et al. , 1990; Jones and
Reichardt, 1990; Maisonpierre et aI. , 1990; Rosenthal et aI., 1990), and
neurotrophin-:4/5 (NT-4/5)(Berkemeier et al. , 1991; Hallbook et al. , 1991; Ip et al.
1992) are structurally related and comprise the neurotrophin gene
family(Korsching, 1993) 
The highest levels of NGF are found in the neocortex and hippocampus 
adult brain, the projection sites of basal forebrain cholinergic neurons, and lower
levels are found within the striatum and other brain regions (Shelton and
Reichardt, 1986; Whittemore et al., 1986). BDNPmRNA is distributed
throughout the adult brain with the highest amounts localized to the
hippocampus and cortex and lower amounts present in the striatum (Hofer et aI.
1990; Wetmore et al. , 1990) and DA neurons of the SNc (Gall et al. , 1992; Seroogy
et aI., 1994). The level of BDNF mRNA expression in the hippocampus exceeds
that of NGF (Hofer et aI., 1990). NT-3 mRNA has been detected in the
hippocampus, cerebellum and cortex of adult brain (Ernfors et aI., 1990; Hohn et
al., 1990; Jones and Reichardt, 1990) as well as DA neurons of the SNc (Gall et al.
1992; Seroogyet al., 1994). In the adult brain, NT-4/5 expression is highest in
the pons-medulla, hypothalamus, and cerebellum, with lower expression found
in the hippocampus, midbrain, striatum and septum (Timmusk et al., 1993).
Other neurotrophic factors. Cilary neurotrophic factor (CNTF), a
member of the alpha-helical cytokine superfamily, is a cytosolic factor (Lin et al.
1989; Stockli et al., 1989). In the adult brain, CNTF mRNA is expressed at
moderate levels in the cerebellum and brainstem and at low levels in other brain
regions including the hippocampus, striatum, cortex, and septum (Stockli et aI.
1991). Glial cell line-derived neurotrophic factor (GDNF) is a member of the
transforming growth factor-B superfamily. GDNF mRNA is widely distributed
in the adult CNS and has been localized to the striatum, hippocampus, cortex
VM, cerebellum, and spinal cord (Choi-Lundberg and Bohn, 1995; Schaar etaI.
1993; Springer et aI., 1994; Stromberg et al., 1993). Basic fibroblast growth factor
(bFGF) is a mitogenic growth factor with neurotrophic activity within the CNS
(Baird, 1994). bFGF mRNA is widely distributed throughout the brain in both
astrocytes and neurons (Gonzalez et aI. , 1995). Platelet-derived growth factor
(PDGF) is also a mitogen and occurs as three isoforms, PDGF- , PDGF- , and
PDGF-BB. Transcripts for both PDGF chains A and Bare found throughout the
brain (Sasahara et al., 1991). Transforming growth factor- (TGF-B) also occurs in
several isoforms. TGF- 2 and 3 mRA is present in cortex, st iatum
hippocampus, cerebellum, and brainstem (Unsicker et al. , 1991).
ecifici and distribution of neurotro hic factor rece tors in the adult
brain Neurotrophins. The biological actions of the neurotrophins are mediated 
by a family of receptor tyrosine kiases, Trks. These high affinity receptors
contain an extracellular domain for ligand recognition, a transmembrane
domain, and a cytoplasmic domain which possesses tyrosine kinase activity
(Meakin and Shooter, 1992). These different receptors each show distinct and
overlapping binding characteristics (Figure 3). The effects of NGF are mediated
via the TrkA receptor (Kaplan et al., 1991a; Kaplan et al. , 1991b; Klein et al.
1991a), whereas BDNF (Klein et al.
, 1991b; Soppet et al., 1991; Squinto et al. , 1991)
Figure 3. Neurotrophic factors and their receptors. The neurotrophins nerve
growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-
(NT-3), and neurotrophin 4/5 (NT-4/5) bind with high affinity to the tyrosine
kinase receptors TrkA, TrkB, and TrkC. ReJative affinities of each factor for the
Trk receptors is represented by arrow thickness. The CNTF receptor complex is
composed of the CNTF receptor (CRa), leukemia inhibitory factor receptor
(LlFRf), and gp130.

and NT-4/5 (Berkemeier et al. , 1991; Ip et aI., 1992; Klein et aI., 1992) activate the
TrkB receptor. NT-4/5 also binds with low affnity to the TrkA receptor
(Berkemeier et aI. , 1991; Ip et al., 1992). NT-3 binds with high affinity to the
TrkC receptor and with lower affinity to both TrkA and TrkB(Cordon-Cardo et
al., 1991; Klein et aI. , 1991b; Lamballe et al. , 1991; Soppet et aI. , 1991; Squinto et
al., 1991). The neurotrophins bind not only to their respective Trk receptors, but
also to the low affinity NGF receptor p75 (Meakin and Shooter, 1992). In
addition to the full length TrkB receptor, there is a truncated form which lacks
the cytoplasmic catalytic kinase domain (Klein et'al. , 1990; Middlemas et al.
1991). Similarly, different forms of the TrkC receptor exist, including a non-
catalytic truncated variant(Tsoulfas et al., 1993; Valenzuela et aI. , 1993).
Trk receptors are expressed widely throughout the adult brain
predominantly by neurons. TrkA receptors are the least abundant and are
expressed by the cholinergic interneurons of the striatum, neurons of the basal
forebrain; aS well as in various brainstem regions (Holtzman et al., 1995; Merlio
et al., 1992; Richardson et al. , 1986; Steininger et aI., 1993). In situ hybridization
studies indicate that there is similar regional expression of TrkB and TrkC
mRA(Altar et al. , 1994c; Merlio et aI., 1992). Transcripts for both receptors are
found in numerous brain regions including the striatum, hippocampus, and
cortex as well as SN and ventral tegmental area (VTA) (Altar et al. , 1994c; Merlio
et' aI. 1992). Additionally, the truncated form of TrkB is localized to the
ependymal lining of ventricles, choroid plexus, and astrocytes (Altar et aI., 1994c;
Klein et al. , 1990).
Other neurotrophic factors. The structure of the CNTF receptor is
unelated to the Trk receptor family and is comprised of three subunits, sharing
components with cytokine receptors for IL-6 and LIF (Davis et al. , 1993; Davis et
aI., 1991;.Davis and Yancopoulos, 1993). mRNA for the CNTF receptor is
distributed throughout the brain, with highest expression in the cerebellum.
High levels are also found in skeletal muscle (Davis et aI., 1991). FGF receptor
. mRNA is widely expressed and is found at high levels in the hippocampus and
at lowerlevels in the midbrain and several other brain regions (Wanaka et al.
1990). PDGF B receptors, which bind the PDGF-BB isoform, are found on
urons in the hippocampus, cerebellum, basal ganglia, and brainstem (Smits et
al. 1991). The effects of TGFB are mediated by a high affinity serine-threonine
kinase receptor (Mass ague, 1992). The receptor for GDNF is not yet known.
aminer ic neurotro hic factors. Due to the trophic effects of NTFs
the supplementation or replacement of a DA NTF may protect or slow the
neuronal degeneration of PD. Several DA NTFs, including BDNF, NT- , NT-4/5,
bFGF, TGFB, and GDNF have recently been characterized (Hyman et al. , 1991;
Hyman et al. , 1994; Hynes et al. , 1994; Knusel et al., 1990; Lin et al., 1993; Mayer
et aI., 1993a; Poulson et al. , 1994).
The effects of the neurotrophins BDNF (Hyman et al., 1991; Hyman et al.
1994; Knusel et al. , 1991), NT-3 (Hyman et aI. , 1994), and NT-4/5 (Hyman et al.
1994; Hynes et al., 1994) as well as GDNF (Lin et al., 1993) on fetal DA neurons
were first demonstrated in vitro. PDGF-BB (Nikkhah et al., 1993b), TGFB
(Poulson et al., 1994) and bFGF also increases DA cell survival in vitro, yet the
effect ofbFGF is thought to be mediated by gHa (Engele and Bohn, 1991; Knusel
et aI. , 1990; Mayer et aI., 1993a). In additon to promoting survival of DA
neurons in culture, the administration of these factors to the intact adult rat brain
is associated with significant behavioral and neurochemical alterations.
Supranigral delivery of BDNF enhances striatal DA turnover and decreases
nigra I DA turnover as well as causes contralateral rotations and locomotor
activity in amphetamine treated rats (Altar et al., 1992; Martin-Iverson et al.
1994). The chronic administration of BDNF above the SN enhances the firing rate
and number of electrically active DA neurons (Shen et at, 1994). The localization
of mRA for BDNF and its receptor, TrkB, to the SNin adult brain suggests that
BDNF may maintain SNc neuronal function in the intact brain, perhaps in an
autocrine or paracrine manner (Altar et aI., 1994c; Gall et aI., 1992; Hyman et al.
1994; Merlio et al., 1992; Seroogy et aI., 1994). Also, exogenous BDNF delivered
to the striatum can act on SNc DA neurons via receptor mediated retrograde
transport (Mufson et al. , 1994).
Similar to the in vivo effects of BDNF, supranigral infusion of NT-4/5
results in increased striatal DA turnover and release as well as contralateral
rotation following the administration of amphetamine (Altar et al. , 1994a), and
NT-3 increases amphetamine-induced contralateral turning and decreases SN
DA turnover (Marti-Iverson et aI. , 1994). Likewise, intranigralGDNF
administration in intact adult rats increases spontaneous and amphetamine-
induced locomotor behavior. These behavioral changes are associated with
increased DA levels and turnover in the SN and increased DA turnover and
decreased DA levels in the striatum (Hudson et al., 1995). In addition, sprouting
of TH fibers near the injection site and increased striatal TH fiber staining were
noted (Hudson et al., 1995). By injecting GDNF into the striatum, it has been
demonstrated that this factor is retrogradely transported to the SN DA neurons
thereby suggesting that GDNF may act as a target derived NTF (Tomac et al.
, 1995b). These actions indicate that NTFs may be able to augment DA neuronal
function in the adult brain.
Of relevance to the neurodegenerative processes of PD, pretreatment of
DA neurons with BDNF protects against the neurotoxic effects of MPP+ and 6-
OHDA in vitro perhaps by increasing levels of the antioxidant enzyme
glutathione reductase (Beck et al. , 1992; Hyman et al. 1991; Spina et al. , 1992).
NT-4/5 (Hynes et al., 1994) , bFGF (Park and Mytilineou, 1992), GDNF (Hou et
al., 1996) , and TGF-fS (Krieglstein and Unsicker, 1994) also protect against the
toxic effects of MPP+ in vitro.
Several DA NTFs can prevent cell death in models of neurodegeneration
in vivo. BDNF has shown variable efficacy in protection in in vivo lesion
paradigms. In rats with partial lesions of the nigrostriatal pathway induced by
striatal infusion of 6-0HDA, concomitant supranigral administration of BDNF
enhances striatal DA metabolism and reverses lesion induced rotational
asymmetry (Altar et al., 1994b) However, BDNF or NT-3 did not alter SN DA
levels nor protect against the loss of striatal DA nerve terminals in this partial
lesion paradigm. Initial studies using BDNF failed to show protection of DA
neurons in the SNc following axotomy of the medial forebrain bundle in rat
(Knusel et al., 1992; Lapchak et aI., 1993). However, another study suggests that
BDNF is neuroprotective in the axotomy paradigm (Hagg, 1994). Also
intra striatal grafts of BDNF-secretig fibroblasts have been shown to prevent DA
neuronal degeneration associated with intrastriatal administration of 6-0HDA
(Levivier et al., 1995).
GDNF is able to protect against SN neuronal degeneration in MPTP
treated mice (Tomac et al., 1995a) as well as in rats following axotomy of the
, medial forebrain bundle (Beck et al. , 1995) or striatal 6-0HDA administration
(Kearns and Gash, 1995; Sauer et al., 1995a). Interestingly, GDNF was shown not
only to be neuroprotective, but also regenerative since administration following
MPTP administration resulted in regeneration of TH fibers (Tomac et al. , 1995a).
Additionally, GDNF administration to the SN 4 weeks after partial 6-0HDA
lesioning of the MFB decreased apomorphine-induced rotational asymmetry,
increased SN DA and DOP AC content, and spared 10% of the SN DA neurons
(Bowenkamp et al., 1995; Hoffer et al., 1994). Additional in vivo studies have
demonstrated that NT-4/5 prevents 6-0HDA denervation-induced changes in
striatal neurotransmitter gene expression (Sauer et al., 1995b). Continuous
infusion of CNTF near the SN has been shown to prevent DA neuronal
degeneration in the SNc following transection of the nigrostriatal pathway in
adult rat (Hagg and Varon, 1993). However, in contrast to the aforementioned
protection by GDNF and BDNF, TH expression was only slightly preserved.
Transplantation of fetal dopaminergic neurons
The rationale for transplanting fetal VM neurons into the parkinsonian
brain is to replenish striatal DA levels and reconstruct the synaptic circuitry
within the striatum. Significant information regarding striatal reinervation and
graft-mediated functional recovery has been attained from animal studies,
leading to the initation and development of fetal cell transplantation as a
therapy for PD.
Initial trans lantation ex eriments. Following the demonstration that
grafts of fetal neurons are able to survive within the adult brain and inervate
the host (e.g., Bjorklund et al., 1976; Stenevi et aI., 1976), subsequent studies
addressed the capacity of grafts derived from the fetal precursor of the SN, the
VM, to produce functional recovery in the 6-0HDA rat model of PD. Graft-
induced behavioral recovery was initially demonstrated following the
transplantation of solid pieces of fetal VM into the ventricle (Perlow et al. , 1979)
or into a cortical cavity above the striatum (Bjorklund and Stenevi, 1979) of 6-
OHDA lesioned rats. Methodological adaptations showed that cell suspensions
of fetal VM tissue grafted directly into brain parenchyma show improved graft
survival relative to solid tissue grafts and also produced rotational recovery
(Bjorklund et al., 1980b; Schmidt et aI., 1981). Use of the cell suspension
technique permits implantation with minimal tissue damage into deeper brain
structures than does the grafting of solid tissue pieces. Moreover, it is possible to
determine the number and viabilty of cells prior to implantation and to graft at
multiple sites (Bjorklund et aI. , 1983a; Bjorklund et al. , 1983b).
ortant variables in cell trans lantation.
Donor age. Appropriate donor age is critical to achieve adequate graft
survival (Bjorklund et aI., 1980b; Schmidt et al., 1981). For cell suspension
grafting, the optimal donor age for transplantation coincides with the
developmental period in which the dopaminergic neurons of the SN differentiate
and undergo their last cell division (Bjorklund et al., 1983a). For rat, this time
point corresponds to embryonic day (ED) 14-15 at which point the crown-to-
rump length (CRL) of the fetuses is approximately 10-14 mm (Bjorklund et al.
1983a; Brundin et al., 1985b), and for human fetal tissue the optimal donor age is
at 6.5 - 9 weeks post-conception (Brundin et al., 1986). Use of older tissue results
in significantly reduced graft survival (Bjorklund et al., 1980b; Bjorklund et al.
1983a; Brundin et al. , 1988a; Brundin et al. ' 1985b). However, donor age is less
constrained when grafting solid tissue (Bjorklund et al., 1980a). Yet, solid tissue
may be more immunogeniG as vasculature wil be at least partially donor-derived
(Broadwell et al., 1987). '
Implantation site: The location of the graft site and subsequent region of
striatal reinervation is important for the restoration of function. There is a
topographic organization in the striatum which is reflected by the finding that
grafts reinervating the dorsal striatum produce rotational recovery (Bjorklund
et al., 1980a; Dunett et aI. , 1983; Dunett et al., 1981a) whereas grafts in the
lateral striatum have no effect on rotation (Dunnett et aI. , 1983; Dunnett et al.
1981b). Conversely, grafts reinervating the lateral, but not dorsat region of the
striatu attenuate sensory deficits induced by 6-0HDA lesions (Bjorklund et al.
1980a; Dunnett et al. , 1983; Dunett et aI. , 1981a; Dunett et al. , 1981b)..
Number of cells. It has been estimated that the yield of surviving
dopaminergic neurons following grafting is only 0. 1 % of the total cell number
intially implanted (Brundin et al., 1985b). Since the degree of rotational recovery
is related to the number of surviving TH neurons, the number of-cells implanted
is of critical importance (Brudin et al., 1988a). For rat-to-rat allografts, 100-200
dopaminergic neurons are necessary for amphetamine-induced rotational
recovery (Brundin et al., 1988a). Similarly, the degree of rotational recovery is
also correlated with extent of reinervation of the dorsal striatum (Bjorklund et
aI., 1980a; Dunnett et al., 1981a). Interestingly, at higher levels of neuronal
survival (Brundin et al., 1988a), striatal inervation (Bjorklund et aI. , 1980a), or
DA release (Strecker et al., 1987), a plateau in behavioral recovery is reached with
additional survival providing no further rotational benefit.
Specificity of tissue. Several lines of evidence demonstrate that the
observed behavioral effects are ctependent on the presence and survival of
dopaminergic neurons within the striatum. Grafting of peripheral nerve (Freed
et aI., 1980), tectal tissue, cortical tissue (Freed et al., 1983), striatal tissue, 
serotonergic cells derived from the raphe nucleus (Dunnett et aI., 1988) does not
produce behavioral recovery. Moreover, if the grafted tissue is removed
(Bjorklund et al. , 1980a), immunologically rejected (Brundin et al., 1989), or
subsequently lesioned with 6-0HDA (Dunett et al., 1988), behavioral recovery
is lost, and rotation values return to pretransplant levels. The lesioning of the
grafted neurons also results in a concomitant decrease in DA levels equal to that
observed in lesion-only controls (Dunett et al., 1988). Since lesioning of the
graft causes loss of behavioral recovery, it may thus be concluded that it is the
graft itself, rather than regenerative or trophic actions, which is responsible for
the observed fuctional effects.
Functional as ects of rafted do aminer k neurons.
Behavioral studies. As discussed above, intrastriatal nigral grafts have
been shown to attenuate apomorphine and amphetamine induced rotational
asymmetry, as well as sensory inattention (Bjorklund et al., 1980b; Bjorklund and
Stenevi, 1979; Dunett et al. , 1983; Dunett et al. ' 1981a; Dunett et al., 1981b;
Perlow et al., 1979). In addition, grafting of DA neurons decreases lesion-
induced spontaneous rotation and restores normal behavior on a T-maze choice
task (Dunnett et al., 1983; Dunett et al., 1981a). However, the extent of
behavioral recovery afforded by neural grafting is not complete as all lesion-
associated behavioral abnormalities are not restored following transplantation.
The adipsia and aphagia induced by bilaterallesioning is not ameliorated
(Bjorklund et al., 1980a; Dunett et al., 1981b). In addition, paw reaching deficits
caused by unilaterallesioris are not improved by mtrastriatal VM grafts (Abrous
et aI., 1993; Dunett et aI., 1987; Montoya et al., 1990) nor by grafts placed in the
striatum and nucleus accumbens (Abrous et al., 1993). More recent studies using
micro grafting technques have achieved greater striatal reinervation (Nikkah
et al. , 1994) as well as improvement on paw reaching tasks suggesting that the
previously observed failure of behavioral compensation is likely due in part to
insufficient striatal reinervation produced by conventional macro grafting
techniques (Nikkhah et al., 1993a).
Neurochemical assessment of grafted neurons. Biochemical (Freed et al.
1980; Schmidt et aI., 1983; Schmidt et al., 1982; Zetterstrom et aI. , 1986) and
electrophysiological (Wuerthele et aI., 1981) studies of VM cells implanted either
into the ventricle, above the striatum, or asa cell suspension into the striatum
indicate that grafted dopaminergic neurons are spontaneously active. Following
ventricular grafting, DA has been found within grafts and at lower levels in the
surrounding striatal tissue, suggesting that behavioral recovery is indeed
mediated by DA release from the graft (Freed et al., 1980). However, with
grafting to the lateral ventricle; it is possible that the DA effects in the striatum
were due to diffusion rather than synaptic integration of graft fibers as fiber
growth into the striatum was found to be limited (Freed et al., 1980). Post-
mortem analyses have demonstrated that transplantation of fetal VM tissue
above or within the dorsal striatum restores striatal DA levels to approximately
13-18% of control levels (Schmidtet aI. , 1983; Schmidt et al., 1982). The DA
turnover rate in the grafted striatum was found to be increased relative to that
observed in the intact striatum, yet lower than that observed in lesion only
controls (Schmidt et aI. , 1983; Scbmidt et al., 1982). In parallel rotational studies
the concentration of DA was found to correlate with the degree of fuctional
. recovery, with a striatal DA level of only 3% of normal necessary to eliminate
rotational asymmetry (Schmidt et aI., 1983; Schmidt et al. , 1982).
In vivo J;icrodialysis measurements of DA and its metabolites within the
grafted striatum further demonstrate transplant-derived restoration of DA
synthesis and release (Strecker et al. , 1987; Zetterstrom et al., 1986). Moreover
the grafted nigral neurons respond to dopaminergic drugs in the same manner as
do intact nigral neurons. For example, amphetamine has been shown to increase
DA release by grafted neurons (Zetterstrom et al., 1986). Microdialysis and
electrophysiological analyses have demonstrated that the DA release by the
grafts is regulated. As is characteristic of dopaminergic neurons, administration
of the DA agonist apomorphine has been found to decrease DA release by the
transplant, indicatig an autoregulatory capacity of the grafted neurons, and
addition of the DA reuptake inhibitor nomifensine increases extracellular DA
indicating the presence of functional reuptake sites on the grafted cells (Strecker
et al., 1987). Similarly, administration of DA agonists has been found to decrease
neuronal activity whereas DA antagonists increase activity (Wuerthele et al.
1981). Graft regulation is also suggested by the observation that behavioral
recovery plateaus at high levels of cell survival, with further neuronal survival
providing no additional behavioral effect (Brundin et al., 1988a; Strecker et al.
1987).
Graft afferent and efferent connections. The observed functional recovery
is associated with outgrowth of graft derived fibers into the striatum and the
formation of synaptic connections between the graft and the host (Freund et aI.
1985; Mahalik and Clayton, 1991; Mahalik et al., 1985). In addition to graft
derived efferent fibers, there is an elaborate synaptic circuitry established within
the graft itself (Bolam et al. , 1987; Doucet et al., 1989), and anterograde tracer and
electron microscopy studies have identified host afferents innervating
intrastriatal VM grafts (Doucet et al. , 1989; Mahalik et aI., 1985). Afferents from
the host cortex as well as a sparse distribution of serotonergic fibers from the host
braintem have been identified within grafts, and synaptic contacts with graft
derived neurons have been observed (Doucet et al., 1989). Interactions with host
striatal fibers appear to be limited to the graft-host interface, and the majority of
the graft is not innervated by striatal afferents which normally project to the SN
(Doucet et aI., 1989; Freund et al., 1985). These findings suggest that the
behavioral recovery and the regulation of grafted neurons may be mediated in 
part by host-graft interactions. Furthermore, the incomplete host-graft
inervation may contribute to the lack of recovery on certain behavioral tasks
following intra striatal VM transplantation(Doucet et al.
, 1989).
Restoration of lesion induced changes at the cellular level. In addition to
the abilty to compensate for lesion induced behavioral abnormalities, grafted
dopaminergic neurons are also able to reverse many lesion associated striatal
receptor and gene expression changes, re-establishing the normal inibitory or
facilitory control by DA. The behavioral finding that fetal VM grafts reverse
receptor supersensitivity as measured by apomorphine induced rotation has
been confirmed at the receptor level as the elevated binding of DA receptor
ligands observed in lesioned rats is normalized by VM grafts (Dawson et aI.
1991b; Freed et al., 1983; Rioux et al., 1991). Furthermore, fetal VM grafts have
been shown to attenuate changes in striatal interneurons and striatal projection
neurons which are associated with DA depletion. For example, the increased
levels of preproenkephalin (Bal et aI., 1993; Cenci et al., 1993) and proenkephalin
mRNA (Mendez et aI. , 1993), as well as the decreased levels of preprotachykinin
(substance P) and prodynorphin mRNA (Cenci et aI., 1993; Mendez et al. , 1993)
associated with 6-0HDA lesioning are attenuated by intrastriatal VMgrafts.
Moreover, grafted DA neurons inibit cholinergic neurons (Dawson et aI. , 1991a)
as well as neuropeptide Y-expressing neurons (Moukhles et al. , 1992) as is
observed in the intact striatum. Grafted rats, like control rats, also exhibit
increased striatal fos expression in response to amphetamine and decreased fos
expression following apomorphie administration (Cenci et al., 1992). These
regulatory effects are thought to be mediated by synaptic neurotransmission as
well as by diffusion of DA from the grafted neurons as effects are observed
beyond the area of reinervation (Cenci et al., 1993; Cenci et al., 1992; Manier et
al. , 1991; Moukhles et al., 1992). While the mechanisms underlying graft-
mediated functional recovery are incompletely understood, the re-establishment
of synaptic circuitry and regulation at the cellular level are likely integral
components for the restoration of fuction.
Xenotrans lantation of fetal do aminer ic neurons. The studies
reviewed above have provided significant information about the properties and
capabilties of transplanted dopaminergic neurons. Similar studies using human
fetal tissue have been conducted in order to characterize the properties of
transplanted human fetal DA neurons and to determine the optimal dissection
and transplantation parameters for clinical use. In addition to defining the
transplantation variables, xenografting into the rat striatum has been a useful
means to address several-issues of CNS immunology as described below.
The optimal donor age for human fetal tissue has been determined to be at
approximately 6.5 - 9 weeks post-conception (Brundin et al., 1986). Human
dopaminergic neurons grafted to the immunosuppressed or athymic adult rat
have been shown to reinervate the striatum, attenuate spontaneous and drug-
induced rotational asymmetry (Brundin et al. , 1986; Brundin et al. , 1987;
Stromberg et aI. , 1986), restore DA release (Brundin et al., 1987), and establish
synaptic connections (Clarke et al., 1988; Stromberg et al., 1989). Graft-derived
axons have been found to extend up to 10 mm, suggesting the long-distance.
growth potential of transplanted human fetal neurons in the adult parkinsonian
brain (Wictorin et al., 1992). Moreover, these axons were found to exhibit target
specificity, reinervatig only those areas normally innervated by dopaminergic
neurons (Wictorin et aI., 1992). The results from these human xenograft
experiments, in combination with grafting fundamentals established from the
allograft experiments, have provided the basis for the ongoing clinical trials of
transplantation of human fetal tissue for the treatment of PD outlined above.
Immunolo ical considerations for neurotrans lantation.
Transplantation into the CNS raises questions regarding the potential for
immunologic reactions against the grafted tissue. The genetic disparity between
, the donor and the host as well as the immunologic status of the recipient at the
time of grafting are critical determinants of graft fate. In addition, the grafting
procedure and site of grafting may also influence survival (see e.g. , Sloan et aI.
1991; Widner, 1995 for review).
Basic immunology. The primary function of the host immune system is
to distinguish between "self" and "non-self" in order to recognize foreign antigens
and protect the host (see Lampson, 1987; Sloan et al., 1991; Widner, 1995; Widner
and Brundin, 1988 for reviews). There are two main components of the immune
system which are responsible for host defenses, classified either as cell-mediated
(T cell) or antibody-mediated (B cell) responses. T cells normally recognize
antigens in association with self-major histocompatibilty complex (MHC)
molecules, cell surface glycoproteins expressed on various cell tyes such 
macrophages and microglia. Different subsets of T cells respond to antigens
presented in association with different MHC molecules (MHC restriction).
Specifically, cytotoxic T cells (CD8) recognize antigens in association with self-
MHC I whereas helper T cells (CD4) recognize processed antigen presented by
MHC n bearing cells. Following helper T cell binding to the antigen-MHC
complex, the helper T cell is activated, resulting in the secretion of cytokines
such as interleukin-2 (IL-2), which serve to amplify the immune response by T
cell proliferation and recruitment of additional cells as well as the promotion of
antibody production. In allograft rejection, cell-mediated responses predominate
whereas in xenografts, preformed antibodies may playa critical role in rejection
(Sloan et aI. , 1991; Widner and Brundin, 1988). In addition to the aforementioned
self-MHC mediated reactions, an additional mechanism may underlie graft
rejection. If a cell expresses an MHC molecule which is similar, yet not identical
to self-MHC, then the host may recognize this as a self-MHC-antigen complex
and an immune response may be initiated.
Immunologic considerations in CNS. The CNS is considered to be an
immunologically privileged site as tissue grafted to the brain, if it is rejected , is
rejected at a slower rate than similar tissue grafted to the periphery. While it was
once believed that the CNS immunologic privilege was absolute, this privilege is
only relative since under given circumstances, immune reactions do occur in the
CNS.
Several factors unique to the CNS are thought to contribute to the relative
immunologic privilege. The brain does not have a lymphatic drainage system
the route by which antigens normally travel to the lymph nodes. However, it has
been shown that antigens in the brain do indeed access area lymph nodes
(Widner et al. , 1988). ' In addition, there are no designated antigen presenting
cells in the brain which, as mentioned above, are necessary for T cell activation.
However, several cell types within the CNS may act as antigen presenting cells
under various circumstances (see Widner, 1993 for review). An additional
mechanism contributing to the privileged status of the brain is the BBB which
provides a barrier to the passage of molecules. However, activated lymphocytes
are able enter the CNS (Wekerle et al., 1986). Yet another unique feature in the
CNS is the paucity of MHC expression by neurons and glia (Lampson, 1987).
However, under certain circumstances, including the trauma associated with
grafting, MHC expression is induced (Lawrence et al. , 1990; Mason et al., 1986;
Neumann et al., 1995; Sloan et al. , 1990).
Various transplantation combinations have been evaluated
experimentally. Syngeneic grafts involve transplantation of tissue between
genetically identical subjects, whereas allogeneic grafts involve transplantation
betw:een individuals of the same species which differ genetically, and xenogeneic
grafts are across species. As described below, the type of tissue grafted, as well
as graft site, and implantation method (cell suspension versus solid tissue)
impact subsequent immune responses and graft survival.
Allografting. Current clinical transplantation trials for PD involve
allografting of human fetal tissue. As the donor and recipient wil assuredly
differ at major (MHC) and minor (non-MHC) transplantation loci, the grafted
tissue wil be immunologically compatible with the host. However, the degree
of immunologic reaction to CNS allografts is not clear, and thus the role of
immunosuppressants in clinical transplantation is not precisely defined. Some
trials use continuous immunosuppression, whereas others use short-term or no
immunosuppression.
Experimental studies have addressed the outcome of grafts derived from
an allogeneic source. In some studies, grafts which differ in either major or
minor tr.nsplantation antigens have been found to survive with varying degrees
of cellular infitrates observed within the grafts (Freed et al., 1988; Low et al.
1983; Mason et aI., 1986; Widner et al. , 1989), whereas other studies have shown
allogeneic graft rejection (Lawrence et al., 1990). Similarly, grafts differing in
both major and minor transplantation antigens have been found to survive in
some studies (Widner et al., 1989), yet more variable survival has been observed
in other studies (Mason et al., 1986; Sloan et al. , 1990). The variabilty in the
outcome of these studies may be due in part to differences in transplantation
sites as well as trauma associated with transplantation technique. It has been
found that intraparenchymal grafts show improved survival relative to
intraventicular grafts, and grafting of solid tissue pieces causes more trauma at
the implantation site than does intraparenchymal cell suspension grafting (Sloan
et aI., 1990).
The evaluation of cellular infiltrates associated with neuronal grafting has
shown the presence of lymphocytic infiltrates and increased MHC expression
(Duan et aI. , 1995a; Lawrence et aI., 199(j; Mason et al., 1986; Sloan et al., 1990).
. For example, in the case of intrastriatal cell suspension grafts, activated
microglia, lymphocytes, and macrophages as well as increased expression of
MHC I and MHC II antigens are observed at the graft site 4 days after
transplantation (Duan et aI., 1995a). . This reaction has been found to subside by 6
. weeks after grafting with no apparent deleterious effects on neuronal survival
suggesting that the duration of MHC expression may be a predictor of
subsequent immune response (Duan et al., 1995a). Notably, a similar mild
cellular response is also found immediately following syngeneic grafting (Duan
et al. , 1995a; Mason et al., 1986).
An important caveat to consider in clinical transplantation is that patients
may undergo staged bilateral transplantation procedures. Thus, the recipient
may be immunized by the first graft, potentially jeopardizing survival of the
second as well as the initial graft. This issue has been addressed experimentally
. by conducting sequential allografts in rats. Allografted rats receiving a
subsequent syngeneic grafts have been reported to show no signs of graft
rejection, however, allografted rats receiving a second allograft have been found
to show either reduced survival of the second graft (Widner and Brundin, 1993),
or similar survival yet increased MHC II staining at the site of the second graft
(Duan et al., 1993). While no deleterious effects were observed on the first graft
rats receiving allografts have been found to be immunized by the grafted tissue
, as shown by increased antibody titers and by increased numbers of alloreactive
cells (Widner and Brundin 1993). The status of the host at the time of
transplantation has been demonstrated to affect graft survival as transplants to
rats systemically sensitized via a skin graft prior to grafting fail to survive (Duan
. et aI., 1995b; Mason et al., 1986). While the peripheral detection of antibodies has
not been found to correlate with the likelihood of graft rejection it does however
indicate that the host has been immunized.
Xenotransplantation. The use of xenogeneic tissue for transplantation
would circumvent many of the practical and ethical issues associated with the
transplantation of human fetal tissue. While the need for immune suppression in
allografting is not yet clear, it is a requirement in the setting of xenografting as
transplantation between species rarely results in sustained graft survival in the
absence of immunosuppression (Pakzaban and Isacson, 1994). Although
xenograft survival has been observed in non-immunosuppressed hosts in a few
instances(Bjorklund et al., 1982; Brundin et al., 1985c; Daniloff et al. , 1985),
Cyclosporine A (Cy A) has clearly been demonstrated to enhance xenograft
survival in numerous transplantation paradigms (Brundin et al., 1985c; Brundin
et al. , 1988b; Finsen et al., 1988b; Inoue et al., 1985). Indeed, meta-analysis of
xenotransplantation studies has shown that Cy A treatment is the most important
factor to achieve xenograft survival, improving graft survival from 30% in non-
immunosuppressed hosts to 74% in the presence of continuous CyA treatment
(Pakzaban and Isacson, 1994). CyA inibits T cell activation, and the
effectiveness of Cy A indicates the involvement of T cell-mediated immune
responses in xenograft rejection. Furthermore, evidence of cell mediated
rejection is found in analyses of cell infitrates following xenografting in non-
immunosuppressed hosts (Duan et aI. , 1995a; Finsen et aI., 1988a; Finsen et aI.
1991; Mason et al. , 1986).
In contrast to the relatively mild immune response associated with cell
suspension grafts of syngeneic or allogeneic tissue, the response to xenogeneic
tissue grafted in the non-immunosuppressed host is sustained and more
vigorous (Duan et al., 1995a;Finsen et al., 1991). Rejection of solid grafts in the
CNS has been considered analogous to allograft rejection in the periphery due to
the similar timecourse and characterization of the cellular infiltrate (Finsen et aI.
1988a). An inflammatory infiltrate in solid grafts has been noted as early as three
days after grafting, peaking at 3 weeks after transplantation (Finsen et aI., 1991).
Early after grafting, MHC I expression has been found to be increased, whereas 2
weeks after graftng MHC II was more highly expressed (Duan et al., 1995a).
While the characterization of the cellular infiltrate present during xenograft.
rejection has revealed predominantly T cells (Finsen et al., 1990), it has also been
suggested that preformed antibodies and complement activation may be
involved (Duan et al., 1995a; Mason et aI., 1986). Indeed, marked tissue damage
can be noted as early as 4 days after xenografting in some studies (Duan et al.
1995a).
Immunosuppressive agents. As discussed above, the immunosuppressive
drug regimen used in clinical trials of fetal neuronal transplantation is variable,
and the optimal approach is not yet known. In general, combinations of three
immunosuppressive agents are routinely used, either Cy A alone or Cy A in
combination with corticosteroids and/or azathioprine. CyA prevents T cell
activation by inhibiting the synthesis of IL-2 and its receptor. Corticosteroids
inibit cytokine production and T cell proliferation, and the antimitotic agent
azathioprine inhibits clonal expansion (Suthanthiran and Strom, 1994).
Conventionally, CyA has been employed in experimental studies of
xenotransplantation. However as indicated above, this agent affords less than
optimal graft survival as on average only 74% of CyA treated grafts survive.
Only recently have other agents been evaluated experimentally in the context of
neuronal xenografting. The corticosteroid methylprednisolone has been shown
to be as effective as Cy A in preventing rejection of mouse to rat cell suspension
xenografts (Duan et al., 1996). In addition, triple drug therapy using CyA
prednisolone and azathioprine is also effective in preventing graft rejection
(Pedersen et al., 1995). Further assessment of immunosuppressive agents 
experimental conditions is clearly necessary to determine the optimal drug
combinations for CNS transplantation. Moreover, evaluation of the rejection
process may facilitate the development of novel approaches to
immunosuppression.
Aims of present studies
The following studies were aimed at determining methods of
neuroprotection and neuronal replacement in rat models of PD. Specifically, the
protective effects of the neurotrophin BDNF were evaluated histologically and
neurochemically in an MPP+ model of SN degeneration. In efforts to address the
mechanism of NTF mediated protection, the ability of NGF to prevent the
generation of the oxidant peroxynitrite was evaluated in an animal model of
mitochondrial toxicity. As an alternative to neuroprotective strategies, neuronal
replacement was evaluated by transplanting fetal porcine VM into the DA
depleted striatum of 6-0HDA lesioned rats and assessing graft-mediated
functional recovery and striatal reinervation.
CHAPTER II
IMPLANTED FIBROBLASTS GENETICALLY ENGINEERED TO
PRODUCE BRAIN-DERIVED NEUROTROPHIC FACTOR
PREVENT I-METHYL- PHENYLPYRIDINIUM TOXICITY TO
DOPAMINERGIC NEURONS IN THE RAT
Abstract
The trophism of BDNF for dopaminergic cells in culture has led to
significant interest in the role of BDNF in the etiology and potential treatment of
PD. In this study, we produced nigral degeneration by infusing MPP+, a
mitochondrial complex I inhbitor and the active metabolite of MPTP, into the rat.
striatum. The subsequent loss of nigral neurons was presumably due to
mitochondrial toxicity after MPP+ uptake and retrograde transport to the SN.
Immortalized rat fibroblasts were engineered to secrete human BDNF and
implanted near the SN 7 days prior to striatal MPP+ infusion. BDNF-secreting
fibroblasts were found to markedly increase nigral dopaminergic neuronal
survival when compared to control fibroblast implants. The observation that
BDNF prevents MPP+ induced dopaminergic neuronal degeneration in.the adult
brain has significance for the treatment of neurodegenerative disorders which
may involve mitochondrial dysfuction, such as PD.
Introduction
The range of neuroprotective effects for any putative neurotrophic molecule
must be determined in in vivo models of neurodegeneration (Anderson et aI.
1988; Frim et al., 1993b; Knusel et al. ' 1992; Kromer , 1987; Schumacher et aI. , 1991;
Sendtner et al., 1992a; Yan et aI. , 1992) before practical application of NTF
neuroprotection can be contemplated (Morgan, 1989). Of particular interest are
NTFs found to protect in vivo against neuronal death caused by mechanisms
similar to those thought to occur in human neurodegenerative disorders
, such as
NGF protection against HD-'like lesions of the striatum (Frim et aI., 1993b;
Schumacher et al., 1991) or CNTF protection in a mouse model of motor neuron
degeneration (Sendtner et al. , 1992b). BDNF (Barde et al., 1982; Hofer and Barde,
1988) promotes the survival of fetal mesencephalic dopaminergic cells in culture
(Hyman et al. , 1991). In vivo BDNF protects holinergic neurons from
degeneration after fimbria-fornix lesions (Knusel et al., 1992) and motoneurons
from degeneration after axotomy (Sendtner et al., 1992a; Yan et al., 1992).
The cellular insults that cause some human neurodegenerative diseases may
be only partially modeled by axotomy-induced cell death (Lams et al. , 1988;
Sofroniew et al. , 1990; Sofroniew and Isacson, 1988). Other insults to cellular
integrity, such as impaired energy metabolism
, may more accurately model the
degeneration seen in HD or PD (Beal, 1992; Choi, 1988; Simpson and Isacson
1993; Wallace, 1992). Indeed, evidence for abnormalities in mitochondrial
function have been found in patients with both of these disorders (Brennan et al.
1985; Parker et al., 1989). A well described animal model of PD is produced by
the systemic injection of MPTP into mice or primates (Burns et al. 1983; Heikkila
et aI., 1984a). MPTP, which is metabolized to the mitochondrial complex I
inhibitorMPP+, causes dopaminergic cell death in the SNc, presumably due to
mitochondrial impairment (Nicklas et aI. , 1985; Nicklas et aI. , 1987). BDNF has
been shown to protect dopaminergic neurons against MPP+ toxicity in culture
(Hyman et aI., 1991). In the present study, we used a model of SNc
dopaminergic neuronal degeneration based on MPP+ mediated mitochondrial
impairment to test whether BDNF can protect dopaminergic neurons against
such insults in vivo.
Materials and methods
Genetic en ineerin and selection of a BDNF-secretin fibroblast cell-
line . Cells used for implantation were generated by infection of an immortalized
rat fibroblast cell line (Rat I, initially provided by M. Rosenberg, UCSD) with a
retrovirus vector carrying a human cDNA encoding a full-length preproBDNF
precursor' identified by sequence analysis (provided by G. Walz and B. Seed
Massachusetts General Hospital) as described (Frim et al., 1993a). Briefly, the
preproBDNF cDNA was cloned into the polylinker region of a retroviral plasmid
, (pL(X)RNL, provided by M. Rosenberg, UCSD) under control of the Moloney
murine leukemia virus long terminal repeat promoter in a construct containing
the Tn5 neomycin resistance gene, as shown in Figure 4A. Recombinant plasmid
was transfected into 
'1- ecotropic retrovirus producer cells by calcium shock
and resultant 
'V- BDNF cells were selected under G418. Retrovirus particles
were isolated from the highest producer, and Rat I cells were infected by
repeated incubations with 
'V- BDNF conditioned media in the presence of
Figure 4. Engineering of BDNF-secreting fibroblasts for transplantation. A.
Schematic of the pL(BDNF)RNL retroviral plasmid used for transfection of the \V-
2 producer cells. PreproBDNF indicates the DNA fragment containing a full-
length human BDNF cDNA inserted into the polylinker region of the plasmid;
rsv, Rous sarcoma virus internal promoter; neoR, neomycin resistance gene; L TR
Moloney murine leukemia (5' ) or sarcoma (3') virus long terminal repeat; ampR
ampicilin resistance gene; ori, E. coli origin of replication. Plasmid is not drawn
to scale. B. Photomicrographs of co-culture of TH immunopositive fetal VM
neurons with confluent plating of fibroblasts. (i) Low power view of cluster of
TH immunopositive cells plated on confluent Rat I-BDNF #7 cells. Note
neuronal morphology and neuritic extensions; (ii) higher power view of
individual TH immunopositive neuron plated on Rat I-BDNF #7 cells. Scale bars
= 20 Jl in both panels. C. Bar graph of effects of co-culture with Rat I fibroblasts
or Rat I-BDNF #7 fibroblasts on TH immunopositive fetal mesencephalic neurons
after 5 days in vitro. Error bars represent S.D. ***, significant to p -: 0.001 by t-
test.
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polybrene. Rat I-BDNF sub-clones were selected under G418 and then screened
for their level of BDNF mRNA production by Northern analysis and for their
level of BDNF secretion by an in vitro rat dorsal root ganglion (DRG) neurite
outgrowth bioassay, as previously described (Frim et al. , 1993d).
Co-culture of BDNF-secretin fibroblasts with fetal ventral
mesence halic neurons. In order to fully confirm the secretion of BDNF by the
selected cell-line (Rat I-BDNF #7), VM neurons were dissected and plated on
confluent cultures of Rat I-BDNF #7 cells in an identical manner to that
previously described (Hyman et aI., 1991). After 5 days, cultures were fixed in
4% paraformaldehyde in phosphate buffered saline (PBS, pH 7.4) for 15 min and
then immunostained for TH (Figure 4B) as described below for tissue sections.
The number of cells per plate was counted in a uniform square centered in the
plate (to avoid edge artifact) of approximately 256 mm . Plates containing areas
of non-confluence were excluded from the cell counting analysis. TH positive
cell counts were averaged from three Rat I confluent plates as control and seven
Rat I-BDNF #7 confluent plates and expressed as mean :t S.D. These two
conditions were compared by t-test to confirm the bioactivity of the secreted
BDNF (Figure 4C).
Cell aration and im lantation in substantia ni ra de eneration
model. Cells were harvested by trypsinization and injected as a suspension in
PBS, with 1.0 mg/l CaCl2, 1.0 mg/l MgCl2' and 0.1 % glucose. Cell count and
viabilty were assessed by trypan blue dye exclusion before intracerebral
injection into rat hosts. Rat I cells not altered by retroviral infection were injected
into control animals.
Under pentobarbital anesthesia (65 mg/kg), 8 male Sprague-Dawley rats
(300-350 gm) were grafted with Rat I fibroblast cells (BDNF(-J) and 8 rats were
grafted with Rat I-BDNF #7 cells (BDNF(+J) (Figure 5). Using a Kopf rat
stereotactic frame, burr holes for grafting into the dorsal tegmentum of the
mesencephalon were made at coordinates calculated from bregma as AP -5.3, L
2.4. Injections were made using a 10 /JI Hamilton syringe at V - 0 calculated
from the dura. A total of 2 X 105 cells were inused over 2 min in a volume of 2
/JI; the needle was withdrawn after a 1 min pause.
Seven days after cell implantation, animals received MPP+ infusions into
the striatum (Storey et al. 1992). In a manner identical to that described above
burr holes f r injection were .calculated from bregma and made at AP +1.0, L -
over 1 min, 100 nmol of MPP+ in 1 /JI was infused at V -4.5 calculated from the
dura. A single animal in the BDNF(-I group did not survive the second surgical
procedure.
Animals were sacrificed 7 days after lesioning while under deep barbiturate
anesthesia by cardiac puncture and perfusion with cold heparinized saline,
followed by 4% paraformaldehyde in PBS. Brain were removed, postfixed in 4%
paraformaldehyde in PBS at 4 , then cryoprotected in 30% sucrose in PBS until
equilbration. Serial sections cut at 40 /Jm on a freezing microtome were stained
with cresyl violet (Nissl) or immunostained for TH (East Acres Biologicals
Southbridge, MA) at a primary antibody dilution of 1:3000.
Figure 5. Schematic diagram of experimental paradigm. Rats were grafted with
BDNF( + I or BDNF( -) cells dorsal to the SN 7 days prior to striatal infusion of
MPP+. Animals were evaluated 7 days after MPP+ administration.
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Mor hometric rocedures. The maximal cross-sectional area of the striatal
lesion, as seen by characteristic neuronal loss after cresyl violet staining, was
determined for each animal and measured as described (Schumacher et al.
1991).5Nc neurons were visually counted bilaterally both on Nissl-stained
sections and on TH-immunostained sections. Since all SNc cell counts are
expressed as a percentage of surviving cells relative to the control cell number on
the non-MPP+-injected side, no correction factors were used. The TH
immunopositive SNc cell counts were independently confirmed by two
observers, one of whom was blinded to the treatment regime.
Statistical anal sis. A ratio of lesioned side to non-Iesioned side (grafted
side to non-grafted side) Nissl stained and TH immunostained SNc neurons was
determined for each animal. These ratios (expressed as percent surviving SNc
neurons on the lesioned side) were compared by t-test for BDNF(-I and BDNF(+I
animals using the program Statview 4.0 (Abacus). In order to assess the local and
retrograde effects of infused MPP+, regression analysis of measured striatal
lesion size versus percent surviving SNc neurons was also performed using the
Statview 4.0 program for Nissl stained and TH immunostained cell counts in
both BDNF( - I and BDNF( + I implanted animals.
Results
. BDNF-secretin fibroblasts. Immortalized fibroblasts were engineered to
secrete BDNF using techniques previously employed for constructing NGF-
secreting fibroblasts (Frim et al. 1993a). As described (Frim etal., 1993d),
transgenIc BDNF mRNA synthesis was screened by Northern blotting of total
RNA from Rat I-BDNF cells followed by hybridization to a radio labeled human
preproBDNF antisense cRNA probe. This analysis revealed an mRNA species of
similar size to previously described preproNGF-neoR mRNA transcribed in the
identical vector backbone (Wolf et al. , 1988).
BDNF secretion by the engieered cells was initially screened by testing Rat
BDNF conditioned media in a neurite outgrowth assay using neonatal rat DRG
explants. Conditioned media from Rat I-BDNF #7 cells, at a dilution of 1:130
supported DRG survival and neurite outgrowth for 7 days after explantation.
Conditioned media from uninfected Rat I cells at a dilution of 1:10 did not
support DRG outgrowth or survival after 7 days.
The presence of BDNF secretion by the highest producing selected sub-
clone was fully confirmed by co-culture of Rat I-BDNF #7 cells with TH
immunopositive fetal VMneurons (Figure 4B) as previously described (Hyman
et aI., 1991). Co-culture of fetal mesencephalic neurons with Rat I cells supported
104:t 9 TH immunopositive cells per plate as compared to co-culture with Rat 
BDNF #7 cells, which supported 241 :t 35 TH immunopositive cells per plate.
This approximately 140% increase in TH immunopositive cells per plate
(significant to p.. 0.001 by t-test) is highly consistent with previously observed
specific biological effects of BDNF on fetal mesencephalic neurons supported 
culture from 2 to 8 days (Hyman et al., 1991).
Striatal infusion of MPP+ and SNc de eneration. The placement of
BDNF-secreting grafts near the SNc and the overall strategy of inducing SNc
degeneration by striatal MPP+ infusion is schematically represented in Figure 6.
The presence of significant striatal lesions due to infusion of 100 nmol of MPP+
Figure 6. Model of SNc degeneration after striatal MPP+ infusion. Panel A
depicts a schematic overview of the SNc degeneration model. The anterior
section (approximately bregma + 1.0) shows a needle tract for MPP+ infusion into
the striatum and a tracing of the lesion 7 days later. The boxed area corresponds
to that shown in Panel B, a cresyl violet stained section through the striatum
showing a typical lesion irduced by MPP+ infusion. Note the cell loss and
shrunken fiber bundles in the area of the lesion. The lower section of Panel A
(approximately bregma - 0) shows an example of fibroblast graft placement and
indicates the location of the SNc in relation to the graft. The boxed area on this
section represents the approximate areas shown in Panels C and D. Panels C and
D depict cresyl violet (Nissl) stained sections taken from a control animal
implanted with a non-secreting (BDNF(-J) graft. Panel C represents the SNc
ipsilateral to the striatal MPP+ infusion where neuronal cell number is markedly
reduced when compared to Panel D, the non-Iesioned contralateral SNc from the
same cresyl violet stained section. Size bar, 100 Jl in panels C and D.

was confirmed in every animal by characteristic neuronal loss after cresyl violet
staining (Figure 6B). The lesion size was quantifiable by selection and
measurement of a maximal cross-sectional lesion area for each animal, as has
been performed previously for excitotoxic lesions in the striatum (Frim et al.
1993b; Schumacher et aI. , 1991). This analysis revealed that there was no
difference between the size of MPP+ induced striatal lesions in the BDNF(-) (5.46
:! 2.61 mm ; mean:! S. ) and BDNF(+I groups (5.57:: 2.02 mm ) indicating that
the infused MPP+ had the same potential toxicity in both treatment groups.
Effects of BDNF-secretin
g g
rafts on SNc cell survival. Graft placement
was confirmed on Nissl stained sections, though both the BDNF(-I and BDNF(+I
grafts tended to extend out from the injection tract in the mesencephalic
tegmentum and into the dorsal and ventral paramesencephalic cistern on the side
of the implantation (Figure 6A). For this reason it was impossible to obtain an
accurate estimate of graft size in every animal; however, no obvious differences
were noted between the overall amount of surviving BDNF( 
- I and BDNF( +)
fibroblasts at the time of sacrifice. In particular, all animals seemed to have a
significant number of implanted fibroblasts either within the mesencephalon or
adjacent to the midbrain in the paramesencephalic cistern. This placed grafted
cells within 1 to 2 mm of the SNc on the grafted side in all animals.
Cell counting of Nissl stained neurons within the lesioned (Figure 6C) and
non-Iesioned (Figure 6D) SNc of animals grafted with BDNF(-I cells showed a
53% decrease in neurons on the lesioned side, to 47:: 11 % of the non-Iesioned
side, consistent with previous observations of SNc degeneration in this model
(Srivastava et al., 1993). There was a significantly greater reduction in TH
immunopositive cells than in Nissl stained neurons (p 0: 0.017) in the SNc on the
side of the striatal lesion in BDNF( 
- I implanted animals, to 35 :: 15% (Figure 7).
Particularly noteworthy is a very high inverse correlation (r = 0.921 , F = 27.957
, P
0: 0.003) between striatal lesion cross-sectional areas and percent Nissl stained
SNc neurons on the side of the lesion in animals implanted with BDNF(-I grafts.
This emphasizes the utilty-of this model for studying MPP+ mediated SNc
degeneration. The correlation between striatal lesion sizes and TH
immunopositive SNc cells approached significance (r = 0.709, F = 5.053, po:
075) (Figure 8).
Placement of BDNF( + I grafts near the SNc on the lesioned side resulted in
a significant (p 0: 0.001) increase in the percentage of surviving Nissl stained
neurons to 86:! 18%, and rendered the correlation between striatal lesion size
and SNc cell survival not significant (r = 0.394, F = 0.919
, P = 0.382). The effect of
the BDNF-secreting grafts on TH cell survival was also dramatic (p 0: 0.001) in
that BDNF( + I grafts promoted the survival of 83 :: 22% of the TH
immunopositive SNc cells on the side of the lesion (Figure 78). The magnitude of
these changes can be seen graphically in Figure ro. As observed for the counts
of Nissl stained neurons, BDNF( + I grafts reduced the inverse correlation between
striatal lesion size and TH immunostained surviving cells to r = 0.321 from r =
709 in the BDNF(-I implanted animals. The regression analyses of striatal
lesion sizes on percentage SNc Nissl stained neuronal survival and SNc TH
immunostained cell survival are depicted graphically in Figure 
Figure 7. Effects of BDNF-secreting fibroblast implants on dopaminergic cell
degeneration in the SNc. Depicted are TH immunostained cells found in the SNc
(i) ipsilateral to striatal MPP+ infusion with a BDNF(-I graft (Panel A), (ii)
contralateral to striatal MPP+ infusion in with a BDNF(+l graft (panel B), and (iii)
ipsilateral to MPP+ infusion in a BDNF( + I implanted animal (Panel C). There is a
marked reduction in TH immunopositive cells after MPP+ infusion in the
BDNF(-I implanted animals (Panel A) when compared to a section at a similar
level in the SNc contralateral to an MPP+ infusion (Panel B). Relative to the
BDNF(-I animal (Panel A), the number of SNc TH immunopositve cells spared
ipsilateral to the striatal MPP+ infusion in the BDNF( + 1 implanted animal (Panel
C) is markedly increased and seems to approach the corresponding non-Iesioned
SNc in Panel B. Panel D displays a graphical representation of the effects of the
BDNF(- I and BDNF( + I grafts on cell sparing in the SNc, both for cresyl violet
(Nissl) stained neurons as well as TH immunostained neurons (mean:t SD). Cell
survival is expressed as a percentage of the number of SNc neurons found
contralateral to the MPP+ infusion. Scale bar in Panel B, 100 J.; Panels A, B, and
C are of identical magnification; *, difference significant to p .: 0.001.
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Figure 8. Regression analysis graph of striatal lesion maximal cross-sectional
area versus cell survival in BDN (-) and BDNF(+I implanted animals. This
figure shows a summary of data points for each animal analyzed in this study.
The squares represent SNc Nissl stained neuronal counts, the circles represent
SNc TH immunopositive cell counts. Cell survival in the SNc ipsilateral to the
MPP+ infusion within each animal, expressed as a percentage of the unaffected
contralateral side, is graphed versus maximal striatal cross-sectional lesion area
for BDNF(-) (open circles and squares) and BDNF(+I (closed circles and squares)
animals. The unbroken line represents the regression line (r = 0.921 , F = 27.957)
of cresyl violet stained neurons in the SNc ipsilateral to the MPP+ infusion
against striatal lesion size in control (BDNF( 
- D animals. The broken line
represents the corresponding regression for TH immunopositive SNc cells (r =
709, F = 5.053). Implantation of BDNF(+I grafts, aside from markedly
increasing the percentage cell survival (all closed circles and squares lie above
the BDNF(-I regression lines), resulted in no correlation between cell survival
and the striatal lesion sizes (r = 0.394 for cresyl violet stained SNc neurons; r =
321 for TH immunostained neurons). This implies that the BDNF( + I cell
counts, as shown by the closed circles and squares, now depend on variables
independent of the striatal lesion sizes, such as degree of BDNF delivery.
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Discussion
We have constructed immortalized rat fibroblasts capable of synthesizing
and secreting transgenic human BDNF in amounts adequate to support
explanted DRG neurite extension and dopaminergic neuronal survival in culture.
Implantation of these fibroblasts near the SN in rats 7 days before striatal
infusion of MPP+ significantly protected against subsequent SNc TH
immunopositive neuronal death. e increased number of TH immunopositive
cells in BDNF( + I animals reflects actual cell sparing, as opposed to changes in TH
immunoreactivity, since the number of Nissl stained SNc neurons was also
markedly reduced in BDNF(-I animals, consistent with neuronal death. Nissl
stained neurons were significantly spared in BDNF( 
+ I animals when compared
to BDNF( - I controls.
In addition to a local lesion, infusion of MPP+ into rat striatum causes a
profound loss of dopaminergic SNc neurons (Srivastava et al. , 1993; Storey et aI.
1992). This is presumably due to the uptake of MPP+ by dopaminergic terminals
in the striatum and retrograde transport to the SNc (Campbell et al., 1990). In the
present study, the loss of SN neurons was highly correlated with striatal lesion
size. This correlation between striatal lesion size and SNc cell loss implies a
similar cause for both striatal and SNc neuronal death. Since other insults that
cause massive striatal excitotoxic lesions, such as toxic levels of NMDA-receptor
agonists, do not cause appreciable SNc cell loss (Isacson et aI. , 1985), the cause of
the SNc degeneration would likely be direct MPP+ effects on SNc neurons, not
an indirect effect from the striatal neuronal death. The neuronal death in the SN
is likely caused by mitochondrial blockade after retrograde transport of MPP+
from striatum to SNc and therefore acutely models the dopaminergic cell loss
seen in PD. Interestingly, patients with PO can manifest mitochondrial defects
(Parker et al. , 1989; Shoffner et al., 1991), or more specifically, a deficiency in
mitochondrial complex I activity (Schapira et al. , 1990).
The protective effects of BDNF on survival of dopaminergic neurons in this
model likely reflect a trophic influence on neuronal function, perhaps through
increased mitochondrial efficiency or by induction of cellular protective
mechanisms. Mechanisms of neurotrophin-mediated neuroprotection in the
adult brain are poorly understood. NGF, the most extensively investigated
neurotrophin, is known to modulate a number of intracellular events, including
changes in intracellular calcium stores Gohnson et al., 1992), Na+ /K+ ATPase
activity (Sendtner et aI., 1988), CI- flux (Rothman, 1985) and induction of the
peroxidative enzyme, catalase, both in culture Gackson et al.
, 1990) and in vivo
(Frim et aI., 1994b). BDNF protects cultured neuroblastoma cells against MPP+
and 6-hydroxydopamine toxicity, and induces a 100% increase in the activity of
glutathione reductase, a protective enzyme (Spina et al., 1992). However, BDNF
had no effect on catalase activity in that system.
NGF and BDNF share signficant homology (Leibrock et al., 1989), both are
able to bind to a low affity neurotrophi receptor (Rodriguez- Tebar et al.
1990), and both bind with high-affinity to specific members of the trk-family 
receptors (Kaplan et aI. , 1991a; Soppet et al. , 1991; Squinto et aI., 1991). It seems
possible that BDNF may also mediate similar intracellular changes to those
described for NGF. There also exists a level of specificity in neuronal
populations for neurotrophin activity, for example, NGF does not protect
cultured dopaminergic neurons against MPP+ toxicity (Hyman et al., 1991).
bFGF, on the other hand, does have some protective effects against MPTP
toxicity in the mouse (Otto and Un sicker, 1990) but does not share homology
with BDNF. The suggestion has been made that bFGF may cause glial cells to
secrete neurotrophic factors which in turn effect neuronal protection (Engele and
Bohn, 1991). These observations imply either multiple, complementary
protective pathways for neurotrophic support, or a final common pathway,
which can be activated through a number of receptors.
In vivo BDNF protects against cholinergic neuronal degeneration after
fimbria-fornix lesioning (Knusel et al. , 1992), and ameliorates motor neuron
death after axotomy (Sendtner et al. , 1992a; Yan et al., 1992). However, previous
investigations of in vivo effects of BDNF failed to show any protective effects on
SNc neurons after medial forebrain bundle transection (Knusel et al., 1992). Our
paradigm investigated BDNF amelioration of mitochondrial impairment in '
neurons, perhaps a more limited neurodegenerative insult than proximal
axotomy. The cellular response to axotomy is complex (Lams et al. , 1988;
Sofroniew et al., 1990; Sofroniew and Isacson, 1988) and may not model the
neuronal loss seen in neurodegenerative conditions.
Our observations that BDNF can protect dopaminergic neurons in the SNc
against mitochondrial blockade indicate that adult SNc neurons stil respond to
neurotrophic input and perhaps require neurotrophic support for survival
particularly during aging, when mitochondrial function deteriorates (Wallace
1992). The finding of protective effects of CNTF on dopaminergic neurons in vivo
also supports the idea of neurotrophic input as means to prevent lesion-induced
degenerative changes in the dopaminergic system (Hagg and Varon, 1993).
Insufficient neurotrophic input in the adult, or failure to increase neurotrophic
support as mitochondrial function fails, may render SNc neurons more
vuInerable to environmental toxins or to potentially toxic conditions within the
SNc (Isacson, 1993). In such a case, replacement or supplementation of
endogenous trophic support with BDNF input may increase the likelihood for
SNc neuronal survival in a state of mitochondrial deficiency or oxidative, stress.
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CHAPTER III
CELL-MEDIATED DELIVERY OF BRAIN-DERIVED
NEUROTROPHIC FACTOR ENHANCES DOPAMINE LEVELS
IN AN MPP+ RAT MODEL OF
SUBSTANTIA NIGRA DEGENERATION
Abstract
BDNF promotes the survival of fetal mesencephalic dopaminergic cells
and protects dopaminergic neurons against the toxicity 
of MPP+ in vitro. Supra-
nigral implantation of fibroblasts genetically engineered to secrete BDNF
attenuates the loss of SNc dopaminergic neurons associated with striatal infusion
of MPP+ in the adult rat. Using this MPP+ rat model of nigral degeneration
, we
evaluated the neurochemical effects of supranigral, cell-mediated delivery of
BDNF on SN DA content and turnover. Genetically engineered BDNF-secretig
fibroblasts ( 12 ng BDNF /24h) were implanted dorsal to the SN 7 days prior to
striatal MPP+ adminstration. The present results demonstrate that BDNF-
secreting fibroblasts, as compared to control.fbroblasts, enhance SN DA levels
ipsilateral as well as contralateral to the graft without altering DA turnover. This
augmentation of DA levels suggests that local neurotrophic factor delivery by
genetically engineered cells may provide a therapeutic strategy for preventig
neuronal death or enhancing neuronal function in neurodegenerative diseases
characterized by dopaminergic neuronal dysfunction such as PD.
Introduction
The trophic support and neuroprotection afforded by neurotrophic factors
in in vitro systems and in in vivo neurodegeneration models indicate the possible
therapeutic applicabilty of these factors to neurodegenerative disorders (Hefti
1994; Jelsma and Aguayo, 1994; Lindsay et al., 1993). NGF, the most extensively
characterized neurotrophin, protects against cholinergic neuronal degeneration
induced by fimbria-fornix transection (Hefti, 1986; Kromer, 1987; Rosenberg et
al., 1988; Wiliams et aI. , 1986). More recently; GDNF as well as BDNF have
shown neuroprotective effects in animal models of PD (Beck et al., 1995; Frim et
aI. , 1994a; Tomac et al., 1995a)
The effects of the neurotrophin BDNF on fetal VM dopaminergic neurons
was first demonstrated in vitro (Hyman et aI. 1991; Hyman et al., 1994; Knusel et
aI., 1991). In addition to promoting survival of dopaminergic neurons in culture
the administration of BDNF to the intact adult rat brain is associated with
significant behavioral and neurochemical alterations. BDNF (12 Jlg/ d for 14
days) delivered above the SN via osmotic pump enhances striatal DA turnover
and decreases nigra I DA turnover in amphetamine treated rats (Altar et aI.
, 1992;
Martin-Iverson et al., 1994). These neurochemical changes are accompanied by
behavioral alterations with BDNF administration causing body weight loss
contralateral rotation following amphetamine administration, and increased
locomotor activity (Altar et al., 1992; Martin-Iverson et al., 1994). The in vivo
effects of BDNF on dopaminergic cell function are further demonstrated by the
finding that BDNF (2 Jlg/ d) enhances the behavioral recovery associated with
VM cells grafted into 6-0HDA lesioned rats (Sauer et al., 1993). Moreover
chronic administration of BDNF (12 Jlg/d for 14 days) above the SNc enhances
the firing rate and number of electrically active dopaminergic neurons (Shen et
aI., 1994). The localization of mRNA for BDNF and its receptor, TrkB, to the SN
in adult brain suggests that BDNF may serve to maintain SNc neuronal function
in the intact brain, perhaps via an autocrine or paracrine manner (Altar et aI.
1994c; Gall et al., 1992; Hyman et al. , 1994; Merlio et al. , 1992; Seroogy et aI.
1994). In addition, exogenous BDNF delivered to the striatum may act on SNc
''I'
dopaminergic neurons via receptor mediated retrograde transport (Mufson et aI.
1994).
Of relevance to the neurodegenerative processes characteristic of
Parkinson s disease, pretreatment of VM cells with BDNF protects againt the
neurotoxic effects of MPP+, the active metabolite of MPTP, and 6-0HDA in vitro
perhaps by increasing levels of the antioxidant enzyme glutathione reductase
(Beck et al. , 1992; Hyman et aI. , 1991; Spina et al., 1992). However, BDNF has
shown variable efficacy in protection in in vivo lesion paradigms. In rats with
partial lesions of the nigrostriatal pathway induced by striatal infusion of 6-
OHDA, concomitant supranigral administration of BDNF enhances striatal DA
metabolism and reverses lesion induced rotational asymmetry (Altar et al.
1994b) However, BDNF does not alter SN DA levels nor protect against the loss
of striatal dopaminergic nerve terminals in this partial lesion paradigm. Inital
studies using BDNF failed to show protection of dopaminergic neurons in the
SNc following axotomy of the medial forebrain bundle in rat (Knusel et al., 1992;
Lapchak et al., 1993). However, a more recent preliminary study suggests that
BDNF is neuroprotective in the axotomy paradigm (Hagg, 1994). We have
recently demonstrated that fibroblasts genetically engineered to secrete BDNF
protect against SNc neuronal degeneration induced by the mitochondrial
complex I inhibitor MPP+ (Frim et al.
, 1994a). In this in vivo model of nigral cell
degeneration, striatal infusion of MPP+ results in a loss of 50-75% of Nissl-
stained neurons and approximately 65% of TH neurons in the SNc (Frim et al.
1994a; Srivastava et aI. , 1993), presumably via retrograde transport (Campbell et
aI., 1990) and subsequent inibition of complex I of the mitochondrial electron
transport chain (Nicklas et aI., 1987). Imp antation of BDNF-secreting fibroblasts
in the mesencephalon of adult rats 7 days prior to lesioning attenuated the SNc
dopaminergic cell loss caused by subsequent administration of MPP+ (Frim et
al. 1994a). In the present study we evaluated the effects of genetically
engineered fibroblasts releasing BDNF on DA content and turnover in the SNc in
the MPP+ model of nigral degeneration and show that these transfected
fibroblasts can mediate a neuroprotective effect as well as an enhancement of DA
levels in the SNc.
Materials and methods
Construction of BDNF-secretin fibroblast cell line. An immortalized
fibroblast cell line (Rat- , initially provided by M. Rosenberg, University of
California, San Diego) was genetically engieered to secrete BDNF by infection
with a retrovirus vector containing a human cDNA encoding a full-length
preproBDNF precursor (provided by G. Walz and B. Seed, Massachusetts
General Hospital) as previously described (Frim et al.
, 1993a; Frim et al. , 1994a)
The BDNF transgene was under the control of the Moloney murine leukemia
virus long terminal repeat promoter in a construct containing a neomycin
resistance gene driven by an internal Rous sarcoma virus promoter. Transgenic
clones were selected under the neomycin analog G418 and further characterized
by an in vitro rat dorsal root ganglion bioassay and fetal VM culture assay (Frim
et al. , 1994a).
Northern blot anal sis. BDNF mRNA production by the transfected cell
line was assessed by Northern blottig. Total RNA was extracted from cell
'1'
pellets by guanidinium thiocyanate/cesium chloride centrifugation (Chirgwin et
al., 1979), resolved by electrophoresis in 1.4 % agarose gels containing 2.2 M
formaldehyde (Lehrach et aI., 1977), and transferred to nylon membranes
(Hybond, Amersham). Blots were hybridized overnight to a 32P-Iabeled cRNA
probe, washed, and autoradiographed as described (Frim et al., 1988). The
preproBDNF cRNA probe was synthesized after placement of the full-length
human preproBDNF cDNA into the polylinker site of plasmid Bluscript-
(Stratagene), linearization of the plasmid with HindIII, and transcription with T3
RNA polymerase in the presence of radioactive nucleotide, per product
instructions.
Enz me linked immunoassa . In order to determine the level of BDNF
secretion by the control and transfected cells, BDNF levels were quantified in
four 24 hour samples of conditioned media collected from confluent plates of
BDNF( - I and BDNF( + I cell cultures grown in Dulbecco s medium supplemented
with 10% fetal calf serum. BDNF( + I cells were grown in the presence of 0. 1 %
G418. A sensitive and specific enzyme-linked immunoassay (EIA) detected
mature BDNF protein and did not recognize NT- , NT-4/5, or NGF at
concentrations up to 100 ng/ml (Altar et al. ' 1995). The EIA employed a BDNF-
specific monoclonal antibody of the IgGl isotype as a capture antibody and a
biotinylated, affinity-purified rabbit anti-BDNF polyclonal antibody as a reporter
system. The BDNF EIA was used to measure BDNF levels in 100 III aliquots of
the culture media. The optical density (OD) produced by the colorimetric
reaction of each sample was read on a Thermomax plate reader (Molecular
Dynamics, Menlo Park, CA) at 450 nm with 570 nm correction for plastic
interference. Data were analyzed with the Softmax 881 Software package
(Molecular Dynamics). The lowest concentration of the BDNF standard which
produced an OD value of twice the mean OD value obtained for dilution buffer
only was 10 pg/ml, and a linear range of 10 pg/ml to 1.25 ng/ml was routinely
obtained with the EIA.
Cell aration sur ical im lantation and MPP+ lesion rocedures.
Cells were harvested with trypsin, washed and resuspended in 0.1 M PBS, pH
7.4, with 1.0 Ilg/ml CaCl2, 1.0 Ilg/ml MgCl2, and 0.1 % glucose at a concentration
of lxl05 cells/ill. Cell number and viabilty were assessed by trypan blue dye
exclusion prior to implantation.
Adult male Sprague-Dawley rats (Charles River Laboratories) were
anesthetized with pentobarbital (65 mg/kg, ip) and placed in a Kopf stereotaxic
apparatus. BDNF-secreting Rat-I cells (BDNF(+J, n=8) or control Rat-I cells
(BDNF( - J, n=8) were implanted into the dorsal tegmentum of the mesencephalon
(coordinates relative to bregma or dura: AP: - 3 mm, L: -2.4 mm, V: - 0 mm)
(Figure 9). Using a 10 III Hamilton syringe, a total of 2x105 cells were infused in a
volume of 2 III over 2 minutes followed by a 2 minute pause prior to withdrawal
Figure 9. A. Schematic diagram of coronal rat brain section indicating MPP+
induced striatal lesion area. B. Schematic representation of mesencephalic graft
placement and area dissected for neurochemical analyses. C. Cresyl violet
stained section through striatum of MPP+ lesioned rat. D. TH immunostained
section through the mesencephalon of lesioned, BDNF(-I rat. Note loss of TH-
neurons in the SNc ipsilateral to the lesion relative to the intact side. E. 
immunostained section through the mesencephalon of lesioned
, BDNF( + I rat.
Note neuroprotective effect of BDNF as indicated by the increased cell number in
the SNc relative to the BDNF(-I implanted rat. Scale bar in panel C = 500 /lm
panels C and D = 1 mm.
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of the needle. One week following cell implantation, all rats were anesthetized as
described above and received a 1 /.I striatal infusion of 100 nmol MPP+ over one
minute (coordinates calculated relative to bregma or dura: AP: +1.0, L:-2.5, V:
4.5) (Figure 9) The needle was withdrawn after an additional one minute.
Neurochemical anal sis and histolo . Seven days following MPP+
lesioning, all rats were sacrificed by decapitation under deep pentobarbital 'IIr'1!1
anesthesia, and the brains were rapidly removed. A 3 mm thick coronal section
was cut at the level of the mesencephalon, and the right and left SN were
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dissected on ice as previously described (Isacson et al., 1985) (Figure 9B), placed
in 400 /.I chiled 0.1 M perchloric acid, and frozen on dry ice prior to storage at
80 oc. Samples were sonicated and centrifuged, and the supernatants were
evaluated for levels of DA and 3,4 dihydroxyphenylacetic add (DOP AC) by
HPLC with electrochemical detection as described (Beal et aI. , 1990).
In an analogous series of experiments, animals were implanted with
BDNF(-I cells (n = 7) or BDNF(+I cells (n = 8), lesioned in the aforementioned
manner, and perfused 7 days after lesioning. Serial sections of tissue were either
stained with cresyl violet or immunostained for tyrosine hydroxylase as
described (Frim et aL, 1994a). These histological results have been reported in
part previously (Frim et al. , 1994a).
Statistical anal sis. Comparison of BDNF production by control and
transfected cells was expressed as ng BDNF/105 cells/24 hours and analyzed by
Student' s t-test. Neurochemical data for the left (intact) and right
(grafted/lesioned) SN were analyzed by one-way analysis of variance with
Fisher post-hoc comparison using Statview 4.0 (Abacus).
Results
BDNF mRNA ex ression and BDNF secretion b
y g
eneticall ineered
fibroblasts. Transgenic BDNF mRNA synthesis was confirmed by Northern
blotting of total RNA from BDNF( 
+ I cells followed by hybridization to a
radiolabeled human preproBDNF antisense cRNA probe. This analysis revealed 
single band representing an mRNA species of approximately 5. 1 kB in size (Figure
lOA, Lane BDNF( + 1), consistent with the transgenic construct of preproBDNF-
neoR ' and of similar size to previously described preproNGF-neoR mRNA
transcribed in the identical vector backbone (Wolf et al.
, 1988). Uninfected Rat-
cells (BDNF( - 1) did not contain any hybridization signal (Figure lOA, Lane
BDNF(-1).
BDNF secretion by the engineered cells was quantified by EIA. The
BDNF-transfected cell line produced 6.3.: 0.7 ng BDNF /105 cells/24h (mean.:
SEM) whereas the control Rat-I cell line produced 0.070 .: 0.007 ng BDNF /105
cells/24 h. The secretion rates differed by a factor of 90, and this difference was
highly significant (p = 0.0001) (Figure lOB).
Effects of striatal MPP+ infusion and BDNF-secretin fibroblasts on
SNc . Striatal infusion of MPP+ resulted in a significant lesion and loss of striatal
neurons. A section through the striatum of an MPP+ lesioned rat 7 days post-
lesion is shown in Figure 9C. This striatal lesion is associated with loss of TH-
Figure 10. A. Northern blot analysis of total RNA from BDNF( 
- I and BDNF( + I
cells hybridized to a radiolabeled human BDNF cRNA probe. Note presence of
hybridization band in BDNF(+I cell lane of approximately 5.1 kb (arrow). There
is no corresponding band in the BDNF(-I cell lane. -, 28S RNA. B. Comparison
of BDNF secretion by control (BDNF(-J) and genetically engineered (BDNF(+J)
fibroblast cell line. Transfected cells produce BDNF at a level 90-times above that
of control cells. (n=4 per group; Error bars represent SEM. * p=O.OOOl). Ijli' I
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neurons in the SNc which has been quantified in a parallel series of experiments
to be a loss of approximately 65% (Prim et aI., 1994a). Figure 9 D ilustrates this
loss of TH-IR neurons in the SNc associated with striatal infusion of MPP+ in a
representative rat implanted with BDNF(-1 fibroblasts. Supranigral implantation
of BDNF( + I fibroblasts attenuated this neuronal loss as ilustrated by a
representative section through the VM of a rat implanted with BDNF-secreting
fibroblasts (Figure 9E).
Effects of BDNF-secretin fibroblasts on SN DA levels and metabolism.
DA and DOP AC levels were evaluated in the left and right SN one week
following infusion of MPP+ into the right striatum. There was no side to side
difference in SN DA levels in either the BDNF(-1 or BDNF(+1 implanted groups
one week following striatal MPP+ administration (Figure 11A) However, the
mean DA level was signficantly increased in the BDNF( + I group ( 7.6 .: 0.4 ng
DA/mg protein) as compared to the BDNF(-) group (6.3.: 0.4) ipsilateral to the
lesion. This increase in the BDNF( +) group was also significantly greater than
the DA level in the BDNF(-1 group contralateral to the lesion (6. 0.5),
indicating a supra-normal DA content associated with BDNF delivery. In
addition, on the side contralateral to the implant, DA levels were significantly
increased in the BDNF(+1 group (8. 1.: 0.3) as compared to the BDNF(-1 group.
DA turnover, as measured by DOP AC/DA ratios, was significantly
decreased in both the BDNF(-) and BDNF(+) groups on the side ipsilateral to the
lesion (BDNF (-I = 0.36.: 0.02; BDNF(+1 = 0.36.: 0.02) relative to the
corresponding intact contralateral side (BDNF (-I = 0.42.: 0.01; BDNF(+1 = 0.42.:
02) (Figure 11B). There was no significant difference when comparing the
Figure 11. A. Substantia nigra DA concentration in BDNF(-1 and BDNF(+1
groups ipsilateral (IPSI) and contralateral (CONTRA) to graft and lesion. Mean 
SEM; *p -: 0.05 ,compared to BDNF(-1 CONTRA and IPSI. B. DOPAC/DA ratios
for BDNF(- and BDNF( + I groups on the ipsilateral or contralateral sides
respectively. Mean I SEM; *p -: 0.05; n.s. = non-significant.
BDNF (-) BDNF (+)
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DOP AC/DA ratios from the ipsilateral or contralateral side in the BDNF( + I
group with the respective side in the BDNF(-1 group demonstrating that DA
turnover is independent of BDNF treatment. (Figure 11B).
Discussion
The present study demonstrates that supranigral, cell-mediated delivery
of BDNF is able to enhance SN DA concentration in a rat MPP+ model of
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Parkinson s disease. In a previous study, we found histologically that BDNF is
able to protect dopaminergic neurodegeneration associated with striatal infusion
of MPP+ in vivo (Frim et al. , 1994a). Of note is that these effects are mediated by a
level of BDNF that is substantially lower than that employed in other in vivo
studies of dopaminergic neuronal fuction and nigral degeneration.
Striatal infusion of MPP+ is associated with dopaminergic cell loss in the
SNc due to retrograde transport (Campbell et al. , 1990; Frim et al. , 1994a;
Srivastava et al., 1993). In previous histological studies using this MPP+ model
of nigra I degeneration, we have shown a loss of approximately 65% of TH-
neurons in the SNc (Frim et aI., 1994a; Srivastava et al., 1993). Yet, in the present
study, we found that this decrease in cell number was not associated with a
concomitant decrease in SN DA levels in either the BDNF( + I or BDNF( - I group
one week following MPP+ administra.tion. This maintenance of DA levels
suggests a compensatory increase in DA synthesis by the surviving cells and/or
decreased turnover or decreased release by cells metabolically compromised by
MPP+. Our finding of decreased DOPAC/DA ratios on the side ipsilateral to the
lesion in both the BDNF(+1 and BDNF(-1 groups indicates that striatal infusion of
MPP+ decreases DA turnover in the remaining SN dopaminergic neurons and
thus may contribute to the apparent maintenance of DA levels in the lesioned
SN. Moreover, as MPP+ infused into the striatum is not retrogradely transported
to the VTA (Campbell et al., 1990) thus sparing the neurons in this arE , it is '
, possible that the dopaminergic neurons of this region contained in the dissected
area (see Figure 9B) may contribute to the observed maintenance of DA levels.
Furthermore, it is possible that some dopaminergic neurons 'in the SNc remain
alive yet are not detected by TH immunostaining. Such a loss of
neurotransmitter expression is associated with damage to cholinergic neurons
(Hagg et al., 1988; Lams et al., 1988). However, this scenario is less likely in the
MPP+ paradigm as Nissl staining reveals a similar loss of neurons compared to
TH (Frim et al., 1994a). Moreover, at 5 months following the striatal infusion of
MPP+, there is no reversal of lesion effects (Srivastava et al., 1993). In addition
one cannot rule out the possibilty that the control BDNF( - I fibroblasts may have
some positive effect on maintaining DA levels. Nevertheless, the significantly
higher DA levels in the BDNF(+1 group relative to the BDNF(-1 group ipsilateral
to the lesion neurochemically support our previous histological evidence for
BDNF mediated dopaminergic neurotrophism.
The increase in DA ipsilateral to the lesion associated with BDNF delivery
was also greater than the DA level in the BDNF(-1 group contralateral to the
lesion indicating a supra-normal DA content associated with BDNF.
Furthermore, the finding of elevated DA levels in the BDNF( + I group relative to
the BDNF(-1 group on the side contralateral to the lesion demonstrates that the
implantation of the BDNF-secreting graft has distant effects on the contralateral
SN. This distant effect is unexpected in view of previous data indicating that
exogenous BDNF delivered via pump does not diffuse further than
approximately 1.5 mm in brain parenchyma (Morse et al. , 1993) and suggests that
cell-mediated delivery may faciltate distant effects, perhaps via an association of
BDNF with membrane derived molecules that aid diffusion or by combinatorial
trophic effects with other cell-derived factors (Kennedy et aI. , 1994; Serafin et aI.
1994; Takayama et al. , 1995). Indeed, in the quinolinic acid lesion model of
Huntington s disease, NGF delivered by fibroblasts (Frim et al., 1993d;
Schumacher et al., 1991) or by polymer-encapsulated baby hamster kidney cells
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(Emerich et al. , 1994) implanted prior to lesioning shows ' a greater protective
effect than does NGF delivered via intracranial cannulae at the time of lesioning
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(Venero et al. , 1994). Moreover, consistent with our data, other neurotrophic
factors such as GDNF have been shown to mediate effects in the contralateral SN
by diffusion from the injection site (Tomac et al., 1995a). With respect to the
metabolic effects evaluated in this study, it is noteworthy that while BDNF does
increase DA levels, it does not alter relative DA turnover as evidenced by the
finding that DOPAC/DA ratios did not differ between groups on the right or left
sides.
The enhancement of DA levels in the SN with supranigral delivery of
BDNF may be related to the electrophysiological finding that BDNF enhances
dopaminergic neuronal firing in the SNc (Shen et al. , 1994). These functional
effects are presumably mediated by the interaction of BDNF with its high-affinity
receptor, TrkB, which has been localized to neurons of the adult rat SN (Hyman
et al., 1994; Merlio et aI., 1992). Functional enhancement of dopaminergic
neurons has been demonstrated in association with striatal and supranigral
BDNF infusions (Altar et aI., 1994b; Altar et aI., 1992; Martin-Iverson et aI., 1994).
In contrast, chronic delivery of BDNF has also been suggested to decrease striatal
dopaminergic cell function (Lapchak et al., 1993). However, damage to the SNc
associated with repeated injections may account for this apparently contradictory
finding thereby ilustrating the importance of administration route. The
neuroprotection mediated by BDNF-secreting fibroblasts in the MPP+ rat model
of nigral degeneration (Frim et al., 1994a) is in contrast to other reports in which
BDNF failed to protect against dopaminergic neuronal loss (Knusel et aI. , 1992;
Lapchak et al., 1993). In addition to variations in lesion methodologies as well as
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routes of administration and duration of trophic factor delivery, the dose of
BDNF delivered may be of particular significance in order to achieve optimal
neuroprotection. Previous neuroprotection studies have delivered between 1
and 4.5 micrograms daily or every second day via intraparenchymal injections'
whereas the fibroblasts implanted in the present study secrete approximately 12
ng per day thereby suggesting a dose-response curve in which the optimal
neuroprotective dose in vivo may fall lower than has previously been tested.
Indeed such a dose-response effect has been reported in vitro for the trophic
effects of NT-3 and NT-4 on dopaminergic neurons (Hyman et al., 1994), and
studies ofaxotomized SN neurons as well as axotomized motor neuron rescue
demonstrate a submaximal response with higher doses of BDNF (Hagg, 1994;
Vejsada et al., 1994). As suggested by Vejsada, et al. (1994), high levels of ligand
may result in decreased affnity or down-regulation of th high affnity TrkB
receptor or an up regulation of the inactive truncated TrkB receptor, thereby
accounting for the decreased efficacy of higher doses of BDNF.
The results of the present study neurochemically confirm BDNF-mediated
protection of dopaminergic neurons following mitochondrial blockade associated
with MPP+ and furthermore indicate an enhancement of DA levels caused by
delivery of BDNF by genetically engineered fibroblasts. Of particular
significance is the efficacy of the comparatively low level of BDNF delivery in
this paradigm. The neurotrophic effects of BDNF on dopaminergic neurons 
vivo indicate the potential relevance of BDNF to disorders characterized by
neuronal degeneration and DA imbalance.
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CHAPTER IV
ANTIOXIDATIVE MECHANISM OF NEUROTROPHIC
FACTOR-MEDIATED NEUROPROTECTION AGAINST
MITOCHONDRIAL TOXICITY
Abstract
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NGF-secreting fibroblasts are able to protect against the striatal
neurodegeneration induced by the mitochondrial toxin 3-nitropropionic acid (3-
i/'
NP). In the present study, we have investigated whether the neuroprotective
effects of NGF are mediated through antioxidative mechanisms. Rats were
grafted in the corpus callosum with NGF(+1or NGF(-1 fibroblasts 7 days prior to
the administration of 3-NP. The generation of peroxynitrite was evaluated by
measuring the striatal levels of 3-nitrotyrosine. NGF grafts significantly
decreased the 3-NP induced generation of 3-nitrotyrosine, presumably by
decreasing peroxynitrite formation. These findings suggest that NGF may
protect against neuronal death by inibiting the production of nitric oxide or
decreasing the levels of superoxide radicals, thereby decreasing the generation of
oxidative agents such as peroxynitrite.
Introduction
HD is an autosomal dominant disorder caused by expansion of a CAG
repeat within the IT15 gene (The Huntington s Disease Collaborative Research
Group, 1993). This disorder is characterized clinically by choreiform movements
and cognitive impairment (Martin and Gusella, 1986) and neuropathologically by
progressive degeneration of striatal spiny projection neurons with relative
sparing of striatal NADPH-diaphorase and acetylcholinesterase aspiny """11
interneurons as well as afferent fibers and fibers of passage (Dawbarn et al., 1985; 
Ferrante et aI., 1987; Ferrante et al., 1985; Graveland et aI. , 1985; Kowall et aI.
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1987; Reiner et aI. , 1988). Paralleling the loss of spiny neurons is a significant
decrease in striatal glutamic acid decarboxylase and GABA as well as a decrease
in choline acetyltransferase (Bird et al., 1973; Perry et aI. , 1973).
Although the genetic abnormality underlying HD has been identified, the
precise process of neuronal death remains unknown. Several lines of evidence
suggest that the striatal neurodegeneration may be due to excitotoxicity and/ or
oxidative stress. Indeed, impairments of mitochondrial fuction (Brennan et aI.
1985; Mann et aI., 1990; Parker et al. , 1990) and energy metabolism Genkis et aI.
1993) as well as a preferential loss of glutaminoceptive neurons with NMDA
receptors (Greenamyre et aI. , 1985; Young et al., 1988) and reductions in
calbindin-D gene expression (Iacopino and Christakos, 1990) are found in HD.
While the precise cellular events which cause neuronal death are uncertain
increased intracellular calcium is known to activate numerous deleterious
enzyme cascades resultig in the production of superoxide radicals and nitric
oxide. Peroxynitrite, formed by the reaction of superoxide and nitric oxide, is a
highly reactive oxidant (Beckman et al., 1990) and may contribute to the
neurodegenerative processes in HD (Figure 12).
Administration of the succinate dehydrogenase inibitor 3-nitropropionic
acid (3-NP) produces striatal lesions and behavioral abnormalities characteristic
of HD (Beal et aI. , 1993; Brouilet et al. , 1995). 3-NP results in increased
generation of hydroxyl radicals and 3-nitrotyrosine (Beal et aI. , 1995; Schulz et aI.
1995a), the product ofperoxynitrite mediated nitration of tyrosine (Ischiropoulos
et aI., 1992). The elevations in hydroxyl radicals and 3-nitrotyrosine formation as
..1,
well striatal lesion size are attenuated in copper / zinc superoxide dismutase
transgenic mice, suggesting a decrease in 3-NP induced peroxynitrite formation
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due to increased superoxide scavenging (Beal et aI., 1995). Furthermore, as
inibition of neuronal nitric oxide synthase (nNOS) by 7-nitroindazole (7-NI)
protects against striatal lesions and reduces the increase in 3-nitrotyrosine
associated with 3-NP administration, involvement of nitric oxide in 3-
neurotoxicity is likely (Schulz et aI., 1995a).
We have previously shown that NGF secreting fibroblasts implanted in
the corpus callosum are also able to protect against subsequent 3-NP induced
striatal degeneration ipsilateral to the graft (Frim et al. , 1993c). In the present
study, the mechanism of this NGF mediated neuroprotection was investigated by
evaluating the abilty of NGF to protect against the formation of 3-nitrotyrosine
associated with 3-NP administration.
Figure 12. Formation of peroxynitrite. Peroxynitrite is formed by the reaction of 
superoxide and nitric oxide. Systemic administration of 3-NP results in increased
generation of 3-nitrotyrosine, the product of peroxynitrite mediated tyrosine
nitration.
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Materials and methods
Cell aration sur ical im lantation and 3-NP lesion rocedures.
NGF-secreting fibroblasts (Schumacher et aI., 1991) were harvested with trypsin
washed, and resuspended in 0.1 M PBS, pH 7.4, with 1.0 J.g/ml CaCl2, 1.0 J.g/ml
MgCl2, and 0.1% glucose at a concentration of 1x105 cells/J.l. Cell number and
viability were assessed by ethidium bromide-acridine orange prior to
III 
I'I 'implantation.
Young adult male Sprague-Dawley rats (125-150 g, Charles River
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Laboratories) were anesthetized with pentobarbital (65 mg/kg, ip) and placed in
a Kopf stereotaxic apparatus. NGF-secretig Rat-I cells (NGF(+1, n=12; 177.6 pg
NGF /105 cells/h) or control Rat-I cells (NGF(-J, n=11; 6.7 pg NGF /105 cells/h)
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were implanted into the corpus callosum (coordinates relative to bregma or dura:
AP: +1.6 mm, L: -1.4 mm, V: - 0). Using a 10 J.I Hamilton syringe, a total of
1x106 cells were infused in a volume of 10 J.I over 5 minutes followed by a 5
minute pause prior to withdrawal of the needle. One week following cell
implantation, rats received 3 injections of 3-NP (20 mg/kg, ip, pH 7.4; Aldrich
Chemicals, Milwaukee, WI) at 12 hour intervals. This dosing regimen has
previously been shown to increase the production of 3-nitrotyrosine (Schulz et
al. 1995a). For histological analysis of striatal neuronal loss associated with 3-
administration, an additional group of non-implanted rats (n = 5) was injected
with 3-NP as described above.
Histolo ical anal sis. Two and one-half hours after the final3-
injection, the non-grafted 3-NP treated animals were terminally anesthetized
with sodium pentobarbital and perfused through the left ventricle with 250 ml
cold heparinized saline (1000 units heparin/ liter 0.9% saline) followed by 250 ml
cold 4% paraformaldehyde in 100 mM PBS (pH '7.4). Brains were removed and
post-fixed for 8 hours in this same paraformaldehyde solution before being
transferred to 30% sucrose in PBS (pH 7.4). Following equilbration, series of 40
J.m coronal sections were cut using a freezing microtome and collected in PBS.
Every fourth section was immunostained for the striatal marker dopamine- and
AMP-regulated phosphoprotein 32 KDa (DARP-32) in order to evaluate the .1,
effects of 3-NP on neuronal survival in the striatum. Free-floating sections were
pretreated with 50% methanol and 0.3% hydrogen peroxide in PBS for 
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minutes, rinsed three times in PBS, and then pre-incubated for 1 hour in 10%
normal goat serum (NGS) in PBS prior to overnight incubation with DARPP-
antibody (kindly provided by Dr. PaulGreengard) diluted 1:20 000 in PBS.
Sections were then washed in PBS and incubated with goat anti-mouse
biotinylated secondary antibody (Sigma) diluted 1:200 in 2% NGS in PBS for 90
minutes. After three PBS rinses, the sections were incubated with avidin-biotin
complex (Vectastain ABC Kit ELITE, Vector Labs) for 90 min, rinsed once in PBS
and twice in 0.05 M TBS, then developed with 0.04% hydrogen peroxide and
05% 3, diaminobenzidine (Sigma) in TBS for 5-15 min.
Neurochemical anal sis. Animals were sacrificed by decapitation 2.5
hours after the final3-NP injection (Schulz et al., 1995a), and the brains were
rapidly removed. The right and left striata were dissected on ice from a 2 mm
coronal section, placed in 500 J.I chiled 0.1 M perchloric acid, and frozen on dry
ice prior to storage at -80 oc. Samples were sonicated and centrifuged, and the
supernatants were evaluated for levels of tyrosine and 3-nitrotyrosine by HPLC
---"- -- ---- -.-
with electrochemical detection as previously described (Beal et al. ' 1990).
Tyrosine and 3-nitrotyrosine were measured as described (Schulz et al., 1995a)
and expressed as the ratio of 3"'nitrotyrosine to tyrosine to adjust for differing
concentrations of brain tyrosine.
Statistical anal sis. Data were expressed as a ratio of grafted side to non-
grafted side for each animal. Mean ratios were determined for the NGF( 
+ I and Ilj it"
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:11 aNGF(-1 groups and analyzed by t-test using Statview 4.0 (Abacus).
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Sections through the striatum were immunostained for DARPP-32 in
order to evaluate the effects of 3-NP on neuronal survival. At 2.5 hours
following the final3-NP dose, there was no evidence of striatal cell loss evident
on DARPP-32 staining (Figure 13). Distinct neuronal cell bodies were evident
throughout the striatum at this time point, indicating neuronal survival at the
time of 3-nitrotyrosine evaluation.
The ratio of 3-nitrotyrosine to tyrosine was evaluated for the left and right
striata for all animals in the NGF(-1 and NGF(+1 groups and expressed as the
grafted side relative to the non-grafted side (Fig. 2). This ratio of 3-nitrotyrosine
to tyrosine was significantly reduced in the NGF(+1 group (0.87.: 0.14) relative
to the NGF(-) group (1.28.: 0.
, P =; Figure 14), a decrease of 32%.
Figure 13. DARPP-32 immunostained section through the striatum 2.5 hours
following the third 3-NP injection. A. Note absence of 3-NP induced striatal
lesion at this time point. B. High power view of section shown in A. Cell bodies
are clearly distinguishable. Scale bar = 1 mID (A), 100 Jim (B)
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Figure 14. Effect of NGF-secreting fibroblast graft on 3-NP induced generation of
3-nitrotyrosine in vivo. The ratio of 3-nitrotyrosine to tyrosine was evaluated for
the left and right striata for the 3-NP treated animals in the NGF(+1 and NGF(-)
groups and expressed as the grafted side relative to the non-grafted side. The
ratio of 3-nitrotyrosine to tyrosine was significantly reduced in the NGF( 
+ I group
relative to the NGF(-1 group, a decrease of 32%. Error bars represent SEM. * P 
05.
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Discussion
The present results demonstrate that NGF-secreting fibroblasts implanted
into the corpus callosum, as compared to control fibroblasts, are able to attenuate
the production of 3-nitrotyrosine induced by administration of the mitochondrial
toxin 3-NP. 3-nitrotyrosine is formed by peroxynitrite-mediated tyrosine
nitration, and the reduced production of this marker in NGF(+1 grafted rats
suggests that the neuroprotective effect of NGF may be mediated in part by
!il
reduced peroxynitrite formation. Furthermore, as the reaction of superoxide and
nitric oxide generates peroxynitrite, NGF may increase the' scavenging of
;:1
:1 f
superoxide radicals and/ or decrease the production of nitric oxide
, possibly by
inibiting nNOS. As shown by the histological results, there is no visible
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neuronal damage at the time of neurochemical analysis (2.5 hours after 3-
dosing).
Administration of 3-NP results in the production of hydroxyl radicals and
peroxynitrite as well as striatal neurodegeneration (Beal et al. , 1995; Schulz et al.
1995a). The precise cellular mechanisms involved in this cell death are hot fully
understood. As 3-NP induced striatal lesions are prevented by the prior removal
of cortical-striatal glutamatergic input via decortication
, it is likely that the
observed cell death is a consequence of excitotoxicity secondary to impaired
energy metabolism (Beal et al., 1993). Moreover, the findings that the nydroxyl
radical production and 3-nitrotyosine formation 
associated with 3-
administration are decreased in mice overexpressing SOD (Beal et aI. , 1995) and
in rats treated with the nNOS inibitor 7-NI (Schulz et al., 1995a) indicate a role
for both superoxide and nitric oxide as well as peroxynitrite in 3-NP mediated
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neuronal death. Likewise, the present finding of reduced levels of 3-
nitrotyrosine in NGF( +) rats as compared to the NGF( -) rats suggests that the
neuroprotective effects of NGF may involve a reduction in peroxynitrite
formation.
NGF is able to protect against a variety of cellular insults including
quinolinic acid (Schumacher et aI., 1991) and 3-NP (Frim et al. , 1993c)
excitotoxicity as well as atrophy and death of cholinergic neurons associated
with aging (Fischer et al., 1987) or lesioning (Willams et al., 1986). While the
precise neuroprotective mechanisms remain unclear, evidence suggests that NGF
may increase the activity of antioxidant enzymes such assuperoxide dismutase,
glutathione peroxidase, and catalase (Frim et al. , 1994b; Nistico et al., 1992) as
well as stabilze cellular Na+/K+ ATPases (Varon and Skaper, 1983).
Interestingly, while inhibition of nNOS with 7-NI protects against 3-NP toxicity
(Schulz et al. , 1995a), it fails to protect against the excitotoxic neuronal death
associated with quinolinic acid suggesting that the toxicity of quinolinic acid is
mediated via an NO-independent mechanism (MacKenzie et aI. , 1995). As NGF
is able to protect against both of these excitotoxins, multiple neuroprotective
mechanisms may be induced by NGF.
Impaired energy metabolism, free radicals, and excitotoxicity are likely
involved in the pathogenesis of neurodegenerative disorders such as
Huntington s disease (Beal, 1995). Experimental evidence suggests that
mitochondrial impairment results in secondary excitotoxic cell death (Novell et
al., 1988; Simpson and Isacson, 1993), and the neuronal death caused by 3-
may be attributed to such processes (Beal et al., 1993). The present finding of
reduced 3-nitrotyrosine levels in NGF( 
+ I grafted rats suggests that NGF
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neuroprotection may be mediated in part by reduced oxidative stress due to
decreased peroxynitrite formation. Due to its ability to prevent neuronal death at
the level of oxidative stress, NGF may have applications for future therapeutic
interventions in neurodegenerative disorders characterized by mitochondrial
impairment and oxidative stress such as HD.
Conclusion
As neurodegenerative processes are thought to be mediated by a
combination of excitotoxic mechanisms, free radical damage, and energy
impairment, factors which act at any of these levels may interfere with the
progression to cell death.. Neurotrophic factors are able to protect neurons
against a variety of cellular insults indicating their potential therapeutic value for
the treatment of neurodegenerative disorders (Mattson et al. , 1993). 3-
toxicity is associated with the production of hydroxyl radicals and peroxynitrite
activity. NGF-secreting fibroblasts have previously been shown to protect
against the striatal lesions associated with 3-NP induced mitochondrial
impairment. The reduced formation of 3-nitrotyrosine following 3-
administration in NGF(+1 grafted rats, as compared to NGF(-1 rats, suggests that
the neuroprotective mechanism of NGF likely involves inhibition of
peroxynitrite. The present data suggest that the antioxidative mechanisms
underlying NGF mediated neuroprotection may include superoxide scavenging
as well as inibition of nitric oxide formation. As 3-NP toxicity parallels many of
the histological and behavioral features of HD, neurotrophic factors such as NGF
106
may reduce neuronal vuInerability and protect against ensuing
neurodegenerative processes.
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CHAPTER V
XENOTRANSPLANTATION OF PORCINE FETAL VENTRAL
MESENCEPHALON IN A RAT MODEL OF PARKINSON'
DISEASE: FUNCTIONAL RECOVERY AND GRAFT
MORPHOLOGY
Abstract
Neurotransplantation of human fetal DA neurons is currently being
investigated as a therapeutic modality for PD. However, the practical limitations
of human fetal transplantation indicate a need for alternative methodologies.
Using the 6-0HDA rat model of PD, we transplanted dopaminergic neurons
derived from ED 27 porcine fetuses into the denervated striatum of CyA-treated
or non-Cy A treated rats. Functional recovery was assessed by amphetamine-
induced rotation, and graft survival and morphology were analyzed using
neuronal and glial immunostaining as well as in situ hybridization with a
porcine repeat element DNA probe. A significant, sustained reduction in
amphetamine-induced rotational asymmetry was present in the CyA treated rats
whereas the non-CyA treated rats showed a transient behavioral recovery. The
degree of rotational recovery was highly correlated to the number of surviving
transplanted porcine dopaminergic neurons. TH+ neuronal survival and graft
volume were significantly greater in the Cy A treated group as compared to the
non-Cy A group. By donor-specific neuronal and glial immunostaining as well as
donor-specific DNA labelling, we demonstrate that porcine fetal neuroblasts are
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able to survive in the adult brain of immunosuppressed rats, mediate functional
recovery, and extensively reinervate the host striatum. These findings suggest
that porcine DA neurons may be a suitable alternative to the use of human fetal
tissue in neurotransplantation for PD.
Introduction
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Current therapeutic strategies for the treatment of PD include the
transplantation of human fetal dopaminergic neurons in order to replace
dopaminergic neurotransmission and reconstruct synaptic circuitry. Data from
rat models of PD demonstrate that transplanted human neuroblasts are able to
reinnervate the host brain(Brundin et al. , 1986; Brundin et al., 1988b; Clarke et al.
1988; Stromberg et al. , 1986; Wictorin et al., 1992). In addition, recent clinical
reports indicate long-term survival and fuctional recovery associated with the
transplantation of human fetal ventral mesencephalic tissue into the caudate
and/ or putamen of patients with MPTP-induced (Widner et aI. , 1992) or
idiopathic (Freed et al., 1992; Kordower et al. , 1995; Lindvall et al. , 1994)
parkinsonism. While these intial clinical findings are encouraging, the practical
and ethical limitations inerent to current human neurotransplantation protocols
remain. The survival rate of dopaminergic neurons following transplantation is
approximately 5-10%, and as many as 10-15 fetal VM per patient may therefore
be required for sufficient survival and reinervation (Bjorklund, 1993).
Availabilty of viable human fetal neural tissue is presently a limiting factor, and
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the development of alternate methodologies in clinical transplantation is
therefore necessary.
One approach to increase the availabilty of fetal tissue for surgical
. procedures would be long-term storage of the cells derived from several
embryos. Various storage approaches have been investigated including freezing,
culturing, and cool storage- C) of the harvested tissue. Unfortuately,
cryopreservation of VM cells in liquid nitrogen prior to transplantation has
yielded variable results in experim ntal models (Coller et al., 1987; Frodl et al.
1994a; Redmond et al. , 1988; Sauer et al., 1992). Similarly, while grafted cultured
VM neurons are able to survive (Brundin et al. , 1985a; Brundin et al., 1988a) graft
size has been shown to be markedly reduced relative to fresh tissue
grafts(Brundin et al., 1988a). Interestingly, cool storage of rat or human VM
tissue fragments in hibernation medium for up to 5 or 3 days, respectively, prior
to dissociation and grafting has been reported not to affect graft survival
adversely (Sauer and Brundin, 1991). Indeed, pooled human fetal tissue has been
stored in hibernation medium for short intervals (up to 48 hours at 8 C) prior to
transplantation in clinical trials (Freeman et al., 1995; Kordower et al. , 1995).
However, this approach is temporally limited as graft survival is significantly
reduced following longer storage periods (Sauer and Brundin, 1991). Yet, graft
viabilty has recently been demonstrated using extended periods of cool storage
(up to 8 days) in combination with microtransplantation techniques (Nikkhah et
al., 1995) suggesting long-term cool storage may be clinically feasible.
A further approach to circumventing the limitations associated with
human fetal neural transplantation is the grafting of fetal neuroblasts derived
from a xenogeneic donor. Xenotransplantation allows for the sterile harvesting
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of large quantities of pathogen-free tissue of the desired embryonic age. In a
variety of experimental paradigms, transplanted fetal xenogeneic neuroblasts
survive in and reinnervate the adult host brain (see Pakzaban and Isacson, 1994).
It has previously been reported that xenografts containing DA cells derived from
ED 21-ED 26 porcine VM are able to survive in the immunosuppressed adult rat
(Freeman et al. , 1988; Huffaker et al., 1989). In addition, long-term graft survival
and reduction of amphetamine-induced rotational asymmetry were found in
immunosuppressed rats as compared to non-transplanted and non-neuronal
transplant controls (Huffaker et al., 1989).
Alternatively, the constraint of tissue supply could be over ome by
:i :
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grafting other types of DA releasing cells. Catecholamine-releasing cells derived
from the adrenal medulla have been investigated as a potential autologous tissue
 !: ",,'
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source for the treatment of PD. However, results from these studies have shown
poor graft survival and little sustained therapeutic benefit (Goetz et al. , 1991).
Implantation of cells genetically engineered to release DA may provide an
additional approach to replenishing depleted striatal DA levels. Fibroblasts
genetically modified to express the gene for TH have been shown to release L-
dopa in vivo and attenuate apomorphine-induced rotational asymmetry in 6-
OHDA lesioned rats (Fisher et aI., 1991; Horellou et al. , 1990; Wolff et aI. , 1989) .
More recently, several groups have attempted to infect striatal cells directly with
the TH gene via h rpes simplex virus (During et al., 1994), adenovirus (Horellou
et al., 1994), or adeno-associated virus (Kaplitt et aI., 1994) vectors. Additonally,
virus vectors have been used to infect human neural progenitors prior to
transplantation (Martinez-Serrano et al., 1995; Sabate et al., 1995) suggesting the
potential utilty of ex vivo genetic engineering of progenitor cells. While the
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approach of genetic modification of cells holds promise for future therapeutic
interventions, current methodologies are constrained by limited gene expression
and functional recovery (Bjorklund, 1993; Lindvall, 1995) as well as the
cytopathogenicity and the low rate of infectivity (Isacson, 1995) associated with
virus vectors. Moreover, the constitutive release of DA by non-neuronal cells or
non-dopaminergic neurons may not be as effective in ameliorating parkinsonian
symptoms as compared with the regulated, synaptic release by transplanted
dopaminergic neurons (Bjorklund, 1992; Bjorklund, 1993).
Recognizing the significant constraints of using human fetal tissue for
transplantation and the potential limitations of genetically modified cells
, we
have investigated the ability of porcine neurons to reconstruct neuronal
circuitries in vivo (Deacon et al., 1994; Isacson et aI., 1995). In the present study,
'.!
using the 6-0HDA rat model of PD, we have transplanted neuroblasts derived
from the VM of porcine fetuses (ED 27) into the striatum to further assess the
potential of fetal porcine dopaminergic neurons as a donor source for
transplantation. Graft survival and amphetamine-induced rotation were,
evaluated, and the relationship between neuron survival and the associated
functional recovery as well as the effects of Cy A on these parameters were
analyzed. In additon, xenograft morphology and graft-derived striatal
reinervation were investigated using donor-specific glial and neuronal markers
as well as in situ hybridization with a porcine repeat element (PRE) DNA probe.
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Materials and methods
Lesion surgery. behavioral testing. and experimental groups
. Adult
female Sprague-Dawley rats received a unilateral DA-depleting lesion by
stereotaxic injection of 6-0HDA (3. /lg//ll 02% ascorbic acid in saline) at two
sites (2.5 Ill/site) in the medial forebrain bundle using a 10 /ll Hamilton syringe
(coordinates relative to bregma: AP = - , L = - 8, V = - , incisor bar = +3.4;
AP = -4.4, L = -1.2, V = - , incisor bar = -2.4). 6-0HDA was infused at a rate of 
/ll/min, and the needle was left in place for an additional 2 minutes prior to
withdrawal. All surgeries were conducted under sodium pentobarbital (65
mg/kg, ip) anesthesia in a Kopf stereotaxic frame. Three weeks post-lesion, rats
were tested for amphetamine-induced (5 mg/kg, ip) rotational asymmetry using
automated rotometers (San Diego Intruments) (Ungerstedt and Arbuthnott
1970) (Figure 15).
Twenty-four rats with a net ipsilateral rotation (ipsilateral rotations minus
contralateral rotations) greater than 800 rotations per 90 minutes, reflecting an
approximate 97% DA depletion (Schmidt et al.
, 1982), were divided into two
experimental xenotransplantation groups balanced with respectto pre-transplant
rotation scores. In group A (n = 12), rats received daily injections of Cy 
(Sand immune; 10 mg/kg, diluted in olive oil, sc; Sandoz, East Hanover, NJ)
commencing one day prior to transplantation. We have previously shown this
dose to be effective (Pakzaban et al., 1995). In group B (n = 12), rats received no
Cy A. Cy A treated rats received tetracycline (Panamydn; approximately 20-
mg/kg/ d; Upjohn, Kalamazoo, MI) via their drinking water (250 mg/l)
beginning 30 days after transplantation. All rats received preoperative doses of
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Figure 15. Schematic diagram of transplantation and behavioral testing methods.
A cell suspension of fetal porcine VM was prepared and subsequently implanted
unilaterally into the 6-0HDA denervated striatum. At approximately 4 week
intervals post-transplantation, rats were tested for amphetamine-induced
rotational asymmetry.
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the antibacterial agent cephalothin (Kefln; 10 mg/kg, sc; Lily, Inc., Indianapolis,
Indiana) and the anti-inflammatory agent methylprednisolone (Depo-Medrol; 5
mg/kg, im; Upjohn, Kalamazoo, MI). Rotational asymmetry was monitored at 4-
6 week intervals following transplantation to assess the graft-associated
functional recovery. One rat from Group A died during transplantation surgery
and one rat from Group B died following amphetamine rotation.
Pre aration and trans lantation of orcine fetal ventral
mesence halon. Fetuses were obtained from ultrasound-confirmed pregnant :'r
I'''
Yorkshire pigs 27 days post-insemination according to the standard procedures
of Tufts University School of Veterinary Medicine (Grafton, MA). Fetuses (CRL
= 21 mm) were removed to a dish with cold sterile calcium- and magnesium-free
Dulbecco s PBS, and the VM was dissected from the surrounding tissue and
collected in a petri dish containing Dulbecco s PBS. The VM fragments were
incubated at 37 C for 10 minutes in 1.5 ml of pre-warmed 0.05% Trypsin-0.53
mM EDT A (Sigma) in calcium- and magnesium-free Hanks Balanced Salt
Solution (HBSS). The tissue then was washed four times with HBSS with 50
/-g/ml Pulmozyme (human recombinant DNase; Genentech, San Francisco, CA),
and then gently triturated through a series of fire-polished Pasteur pipettes of
decreasing diameter until a cell suspension containing single cells and small
clumps of cells was obtained. Cell number and viability were determined under
fluorescence microscopy using acridine orange-ethidium bromide as previously
described(Brundin et al. , 1985b).
Rats were anesthetized as for lesioning and were grafted in the denervated
striatum with a suspension of approximately 200, 000 VM cells. Using a 10 /-l
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Hamilton syringe, 2 JlI of the VM cell suspension was injected at each of 2 striatal
sites at a rate of 1 JlI /min followed by a 2 minute pause prior to withdrawal of
the needle (coordinates relative to bregma: AP = +1.5, L = - 8, V = - 0 to -4.5;
AP = +0.5, L = - 0, V = - 0 to -4.5, incisor bar = -3.3).
Perfusion and histolo ical rocessin . Nineteen weeks post-
transplantation, animals were terminally anesthetized with sodium pentobarbital
and perfused through the left ventricle with 250 ml cold heparinized saline (1000
units heparin/ liter 0.9% saline) followed by 250 ml cold 4% paraformaldehyde
in 100 mM PBS (pH 7.4). Brains were removed and post-fixed for 8 hours in this
same paraformaldehyde solution before being transferred to 30% sucrose in PBS
(pH 7.4). Following equilbration, series of 40 Jlm coronal sections were cut using
a freezing microtome and collected in PBS.
Every sixth section was stained with cresyl violet in order to evaluate graft
survival. To assess neuronal survival and graft morphology, adjacent sections
were immunostained by the avidin-biotin peroxidase method (Vector Labs
Burlingame, CA) for TH, donor-derived neurofilament, or donor-derived glia.
To immunostain donor neurofilaments, a monoclonal antibody to neurofilament
000 mol. wt. (rat adsorbed, NF70; Biodesign, Kennebunkport, ME) was used
and a monoclonal antibody againt porcine cluster of differentiation antigen 44
(CD44; Diacrin, Inc., Charle town, MA) was employed to identity donor glia.
Free-floating sections were pretreated with 50% methanol and 0.3% hydrogen
peroxide in PBS for 20 minutes, rined three times in PBS, and then pre-
incubated for 1 hour in 10% normal blocking serum (NBS; normal goat serum for
TH and NF70; normal horse serum for CD44) in PBS prior to overnight
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incubation with primary antibody. TH antibody (Pel-Freez, Rogers, AK) was
diluted 1:250 in PBS containing 1 % normal goat serum, 1% bovine serum
albumin, and 0.1% Triton-X 100, NF70 was diluted 1:1000 in PBS, and CD44 was
diluted 1:2000 in PBS. Sections were then washed in PBS and incubated with
goat anti-rabbit (TH; Vector Labs), goat anti-mouse (NF70; Sigma), or horse anti-
mouse (CD44; Vector Labs) biotinylated secondary antibody diluted 1:200 (TH
CD44) or 1:1000 (NF 70) in 2% NBS in PBS for 90 minutes. After three PBS rinses,
the sections were incubated with avidin-biotin complex (Vectastain ABC Kit
ELITE, Vector Labs) for 90 min, rinsed once in PBS and twice in 0.05 M TBS, then
developed with 0.04% hydrogen peroxide and Q.05% 3 diaminobenzidine
(Sigma) in TBS for 5-15 min.
In selected sections, donor-derived cells were identified via in situ
hybridization with a digoxigenin-Iabelled PRE DNA probe which reacts
specifically with porcine nuclei as described previously (Oettinger et al., 1995),
with the following modifications for brain sections. Briefly, following TH
immunohistochemical.staining, sections were placed onto slides, allowed to dry,
covered with pepsin, and incubated for 15 minutes at 50 C. Following two 5
minute rinses in 2x sodium chloride-sodium citrate (SSC), sections were post-
fixed in 4% paraformaldehyde for 5 minutes at room temperature, rinsed two
times in 2x SSC, and then dehydrated through an ethanol series. Slides were
then dried and covered with a hybridization mixture containing a 234 bp PCR
product digoxigenin-Iabelled PRE probe (25 ng/ml) diluted in Hybrisol VIII
(1:700; Oncor, Inc., Gaithersburg, MD). The PRE probe was generated by PCR
using primers flanking the repeat sequence and labelled with digoxigenin
(Digoxigenin DNA Label Kit, Boehringer Manneim, Indianapolis, IN). Sections
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were covered with a glass coverslip and denatured at 100 C for 10 minutes.
Following overnight hybridization at 37 , slides were soaked in 2x SSC to
remove the coverslips, and sections were rinsed for 10 minutes in a solution of
65% formamide in 2x SSC once at room temperature, once at 37 C, and once at
C. Sections were then rinsed twice in PBS and incubated at room temperature
for 2 hours with an alkaline phosphatase-conjugated anti-digoxigenin antibody
(1:200 in PBS; Boehringer-Manneim, Indianapolis, IN). Following a 10 minute
wash, sections were developed with 5-bromo-4-chloro- indolyl-phosphate/4-
nitro-blue tetrazolium chloride (BCIP /NBT) substrate (Zymed, San Francisco,
CA) and counterstained with nuclear fast red.
:1''
Mor hometric and statistical anal ses. Rotational data were analyzed by
repeated measures analysis of variance (general linear model) with SAS 6.
tli'
(SAS Institute, Cary, NC) followed by CONTRAST and Bonferonni adjustment I/"'l.
for multiple comparisons. Non-linear regression was performed with
DeltaGraph Professional 3.5 (Delta Point, Monterey, CA) using the Marquardt-
Levenberg algorithm. TH + neurons were counted in every sixth section of each
graft and expressed as total number of TH neurons per graft using the
Abercrombie formula(Abercrombie, 1946), and total graft volume was quantified
by measuring CD44+ graft areas with the aid of a computer image analysis
system (Image v. 1.52 for Macintosh) and integrating the cross-sectional areas
across the graft. TH+ neuron survival and graft volume were compared between
groups by unpaired t-test. A value of p .( 0.05 was considered statistically
significant.
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Results
Effects of orcine ventral mesence halic rafts on rotational as met
Amphetamine-induced rotational asymmetry was evaluated at 4-6 week
intervals following transplantation of porcine fetal VM cells into the DA-depleted
rat striatum. Individual net rotation scores for CyA and non-CyA treated rats are
summarized in Figure 16. In the CyA treated group, 8 rats showed a greater than
50% decline in rotation at 8 weeks post-grafting relative to pre-transplant, and a " I
.pI "
II ninth rat showed a reduction in rotation by 13 weeks. Two rats with behavioral
evidence of fuctional grafts at 13 weeks returned to near pre-transplant baselie
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! II'rotation levels by 19 weeks post-transplantation. Two additional Cy A treated
rats did not show any evidence of behavioral recovery during the COurse of the
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study.
A similar time-course of recovery was apparent in the non-CyA rats with
6 out of 11 rats showing a greater than 50% reduction in rotational asymmetry at
8 weeks post-transplantation. An additional rat showed functional graft effects
at 13 weeks post-transplantation. However
, at the end-point of the study, only 4
non-Cy A rats maintained ths reduction. Four of the rats in this group exhibited
no evidence of functional recovery.
There was no significant difference in pre-transplantation net rotation
scores between groups (unpaired t-test). There was a significant effect of time on
rotational behavior across groups (p = 0.0001), yet there was not a significant
group x time interaction. Within group analyses demonstrated that at 8 weeks
following transplantation, both the Cy A and non-Cy A groups showed a
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Figure 16. Amphetamine-induced (5 mg/kg, ip) net rotation asymmetry scores
(turns ipsilateral to lesion minus turns contralateral to lesion during 90 minute
period) plotted for individual rats pre-transplantation and at 4-6 week intervals
post-transplantation. (A) Cy A treated rats (n = 11). (B) Non-Cy A treated rats (n
= 11). In the CyA treated group, 7 rats showed sustained functional recovery (as
defined by a greater than 50% reduction relative to pre-transplant value), 2 rats
showed a transient reduction, and 2 rats showed no evidence of behavioral
recovery. In the non-CyA treated rats, 4 rats showed sustained recovery, 3 rats
showed a transient decline, and 4 rats showed no evidence of recovery. Dark
",,.1'
grey lines represent rats showing sustained recovery, medium grey lines indicate
transient recovery, and light grey lines indicate no evidence of recovery during I't..
the course of the study. III
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significant decrease in rotational asymmetry as compared to their respective pre-
transplant values (Cy A: pre = 1170.0 .: 76. , mean .: SEM, wk 8 = 483.9 .: 167.8, P
= 0.023 ; 'No CyA: pre = 1205.4 89.5, wk 8 = 357.0.: 138.6, P = 0.004). For the
CyA treated group, this attenuation of rotational deficit was maintained for the
course of the study as indicated by the finding that the final rotation value at 
weeks post-transplant (465.: 178.2) did not significantly differ from that achieved
at 8 weeks and remained significantly lower than the pre-transplant value (p =
01). In contrast, while the non-CyA group did show a significant decline in
rotation at 8 weeks after grafting, this correction was not maintained at 19 weeks
post-transplantation at which time the net rotation score (734.4.: 160.1) was
significantly greater than that observed at the 8 week recovery point (p = 0.029).
Furthermore, at the endpoint of the study, the non-Cy A group did not
signifcantly differ from the pre-transplant baseline score.
Survival and size of orcine ventral mesence halic rafts. Neural
xenograft survival was assessed 19 weeks post-transplantation by TH
immunohistochemistry and Nissl staining. Viable grafts, as defined by presence
of surviving neurons, were found in 6 out of 11 Cy A treated animals and 6 out of
11 in the non-CyA group. While there was no difference in rate of graft survival
the average number of surviving TH+ cell bodies in the grafts of the CyA treated
rats (3690 .: 1023, mean .: SEM) was significantly greater than that in the non-
CyA animals (257.: 164; P = 0.0078, Figure 17 A). A similar survival effect was
evident upon measuring the graft volume of sections immunostained for the
donor-specific glial marker CD44 (Figure 178). Mean graft volume in the CyA
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Figure 17. (A) Comparison of the number of surviving TH+ neurons in CyA
treated and non-CyA treated porcine VM xenografts at 19 weeks post-
transplantation. (B) Comparison of graft volume in Cy A treated and non-Cy A
treated rats. Columns represent mean values. Bars represent SEM. * po( 0.05,
unpaired t-test.
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treated group (6.59 mm3 :t1.73) was significantly greater than that of the non-
Cy A rats (0.826 mm :t 0.33, p = 0.0084).
Correlation between TH+ neuron survival and functional recove
Non-linear regression analysis of TH + neuron survival and extent of functional
recovery, as measured by the change in net rQtation, revealed a saturable
relationship (y = 104 x / (77 + xl; r2 = 0.642) indicating that survival of
approximately 80 - 100 TH+ neurons is necessary to achieve a 50% reduction
innet rotational asymmetry (Figure 18). This equation describes the close
correspondence between the degree of functional recovery and the number of
surviving neurons (r = 0.80, P .( 0.01). At a survival of approximately 850 
- 1000
TH+ neurons, behavioral recovery plateaued with additional neuronal survival
providing no further effect on rotation. In each group there was one rat which
showed evidence of behavioral recovery yet, which upon histological analysis
revealed no surviving grafts using available histologic techniques. These animals
were not included in this correlation analysis.
Mor holo and or anization of fetal orcine ventral mesence halic
rafts. In situ hybridization for PRE DNA demonstrated localization of the
majority of porcine-derived nuclei within the confines of the VM graft. Donor-
derived cells were uniformly distributed while the donor TH + neurons formed
clusters within the graft (Figure 19A). PRE DNA labelling revealed a distinct
graft-host boundary (Figure 19B). Porcine cells were not found outside the graft
in the host striatal grey matter yet were observed in host white matter tracts,
particularly the internal capsule and corpus callosum. Since no TH + or NF70+
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Figure 18. Relationship between TH + neuron survival and extent of functional
recovery. Squares (n) represent individual rats form the CyA treated group, and
circles (1) represent rats from the non-Cy A treated group. Non-linear regression
analysis revealed a saturable relationship fit to the equation RR = RR
max * N
/Nso + N where RR = rotational reduction; RRmax = maximum rotational
reduction; N = number ofTH+ neurons; Nso = number of TH+ neurons
necessary to achieve a 50% reduction in rotation (RR 
= 104*N / (77 + NI; r2 =
642).
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Figure 19. (A) Coronal section through intra-striatal VM graft in which donor-
derived cells were identified by in situ hybridization using a probe which
recognizes a pig-specific DNA repeat element. Section is double labelled with
TH and counterstained with nuclear fast red. All blue dots are nuclei of pig-
derived cells. The majority of the donor cells are located within the confines of
the graft, while a fraction of the pig cells have migrated into the host white
matter. (B) Higher magnification of the enclosed area shown in A. Note distinct
graft-host boundary. Scale bar = 500 Jlm (A), 100 Jlm' (B).
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neuronal cell bodies were observed outside the graft, these cells most likely
correspond to CD44+ glia which have migrated into the host white matter
(Figure 19A, B).
In large grafts, the donor-derived TH+ fibers reinnervated the entire
extent of the striatum (Figure 20B). Axons from the graft grew into the grey
matter of the surrounding host striatum, avoiding the penetrating white matter
tracts. This pattern of reinervation was comparable to the normal striatal
inervation by TH+ axons originating from the intact contralateral SN (Figure
20A), and the density of the TH+ fibers in the grafted striatum approached that
observed in the intact striatum (Figure 20A). As shown in Figure 20C, TH+
neuron staining was absent in SN ipsilateral to the 6-0HDA lesion, indicating
that the dense striatal innervation was entirely donor-derived. No TH+ axons
were present in the striatum of rats without surviving grafts (data not shown).
The neuronal and glial organization of ventral mesencephalic xenografts
in the Cy A treated and non-Cy A treated groups was assessed by Nissl staining
as well as TH, NF70, and CD44 immunostaining. Nissl stained sections of CyA
treated rats showed large, neuron-rich grafts which were well integrated with the
host tissue (Figure 21A). The transplants contained large numbers of TH+ cell
bodies with the characteristic morphology of SN DA neurons (Figs. 20B, 21B).
Immunostaining of the porcine VM xenografts for TH revealed organotypic
features of the SN, with large clusters of TH+ neurons at the graft perimeter and
a dense network of TH+ neuronal fibers within the transplant and extending
from the graft to innervate the surrounding host striatum (Figs. 20B, 21B). NF70
immunostaining further demonstrated that the TH-negative regions of the grafts
were densely filed with porcine-derived neurons and fibers (Figure 21C). CD44
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Figure 20. Dark-field photomicrographs from a representative grafted rat
immunostained for TH. (A) Intact striatum. (B) Grafted striatum ipsilateral to
previous 6-0HDA lesion. (C) VM of the same rat as shown in A and B. Note the
absence of dopaminergic cell bodies in the SN and fibers in the striatum
ipsilateral to the 6-0HDA lesion. Scale bars = 500 J.m.
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Figure 21. Adjacent coronal sections through a representative porcine VM
xenograft of a CyA treated rat (A - D) and non-CyA treated rat (E - H) stained for
Nissl (A, E), TH (B, F), NF70 (C, G), and CD44 (D, H). Refer to text for further
description. Scale bar = 200 Jlm.
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immunostaining of donor-derived glia revealed a distinct glial component within
the graft with the most dense labelling observed within the host white matter
tracts penetrating the graft (Figure 21D). Nissl staining of the two CyA treated
rats which showed loss of behavioral recovery revealed a small-cell infitrate and
a limited area of necrosis at the graft site. In addition, there was no evidence of
neuronal graft survival in the two CyA treated rats which showed no behavioral
compensation. A slight scar (approximately 50-100 J.m in width) was present
along the needle tract in these two anmals.
In contrast to the Cy A treated rats
, grafts from non-Cy A rats were
characteristically small and condensed with few surviving neurons as
demonstrated by the limited number of TH and NF70 immunostained cells
(Figure 21E-G). Surviving grafts from this group contained varying degrees of
small-cell infitration. There was greater survival of the glial components of the
graft relative to the neuronal components in this group. In contrast to the Cy A
treated rats, CD44+ immunostaining was usually concentrated in the graft core
and fewer fibers were seen in the white matter tracts (Figure 21H). Of particular
interest, no significant host tissue damage was apparent beyond the transplant
site in rats that did not have surviving grafts at sacrifice.
Discussion
The present results demonstrate that ED 27 porcine VM neuroblasts
transplanted into the DA-depleted rat striatum are able to reinervate the host
and produce functional recovery as measured by a reduction in amphetamine-
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induced rotational asymmetry. These results are consistent with previous
reports of porcine xenografts in rats(Huffaker et aI. , 1989). In the present study,
the extent of behavioral recovery was found to be highly correlated with the
number of surviving TH+ neurons. As demonstrated in other xenograft
paradigms (Brundin et aI. , 1985c; Brundin et aI. , 1988b), immunosuppression
with CyA increased survival of the xenografted TH+ neurons. Using donor-
specific markers and hybridization to a porcine specific DNA repeat element, we
show organotypic cellular organization of TH + neurons and glial components
within porcine VM grafts as well as extensive reinnervation of the DA-depleted
host striatum.
Behavioral effects were apparent in both the CyA immunosuppressed and
non-Cy A rats at 8 weeks following transplantation suggesting the presence of
,,'
''.1'-:
functioning grafts at this time. A similar time course of recovery has been
demonstrated previously following the transplantation of pig ED 21 VM cells
..:
:r'
into CyA treated rats (Huffaker et aI., 1989). Previous studies evaluating
behavioral recovery in rats following transplantation of mouse (Brundin et aI.
W.!-
,,,J.
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1985c; Brundin et al., 1989), rat (Brundin et al. , 1988a; Dunnett et al. , 1983), or
human (Brundin et al. , 1986) dopaminergic neurons have shown the onset of
recovery to be at approximately 3-4 weeks following grafting of mouse or rat
tissue, and 15-19 weeks for human transplants. The intermediate time course of
recovery associated with the grafting of porcine dopaminergic neurons probably
reflects the developmental rate of the pig relative to rodents and humans
(Dickerson and Dobbing, 1967; Sacher and Staffeldt, 1974; Snow and Tam, 1980).
While there was a significant decrease in amphetamine-induced rotation
in both the Cy A and non-Cy A groups 8 weeks after grafting, this effect was not
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sustained in the non-CyA rats. Indeed, at the endpoint of the study, the non-
CyA group had returned to pre-transplant baseline rotation values. Conversely,
at 19 weeks post-transplantation, rotation in the CyA group remained
significantly lower than pre-tranplant values and did not differ from scores seen
at 8 weeks post-transplantation. The CyA group had significantly greater TH+
neuron survival and greater graft volume as compared to the non-Cy A group.
These results demonstrate that under Cy A treatment, porcine VM grafts are able
to survive long-term in the adult host brain and produce sustained fuctional
recovery on amphetamine-induced rotation.
There was a high degree of correlation between the number of surviving
grafted TH+ neurons and the extent of behavioral recovery. Regression analysis
revealed a threshold number of approximately 80-100 neurons necessary to
obtain at least a 50% reduction in amphetamine-induced rotation. It has been
determined that only 3% restoration of striatal DA is necessary for recovery on
amphetamine-induced rotation (Schmidt et at, 1983; Schmidtet at , 1982).
Similar analyses of allografts in the 6-0HDA rat model of PD have demonstrated
a minimum of approximately 100-200 surviving rat DA neurons in order for a
50% reduction in rotational asymmetry (Brudin et al., 1985b). The present
recovery at a neuron number of 80-100 may reflect a larger degree of striatal
reinnervation per porcine neuron or a greater DA output per neuron. Similar to
previous studies, a plateau in rotational recovery was found beyond which
further compensation did not occur (Bjorklund et al., 1980a; Brundin et al., 1988a;
Huffaker et at , 1989) which may be attributable to the autoregulatory capacity of
the transplanted dopaminergic neurons or maximal behavioral response
(Strecker et al. , 1987).
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The specific histological analysis of surviving grafts in the Cy A treated
group showed neuron-rich grafts with TH+ cell bodies located primarily at the
graft-host interface. TH+ axons and dendrites were present within the graft, and
axons extended from the graft to densely reinnervate the grey matter of the entire
grafted striatum. The complete loss of TH+ neurons in the SN associated with
the 6-0HDA lesion (Figure 20C) indicates that these TH+ fibers were entirely
donor-derived. NF70 was used to identify both the dopaminergic and non-
dopaminergic grafted neurons and revealed NF70+ neurons within the TH-
negative regions of the graft. Similar to the dopaminergic reinnervation, NF70+
axons extended into the host striatum as well as into more distant targets
(Isacson et al. , 1995). Neuronal cell bodies were not found outside the grafted
area. CD44 immunostaining revealed donor glia distributed predominantly in
striatal white matter tracts within and around the graft. In addition, glial fibers
and cell bodies were apparent in distant white matter tracts. Using a pig-specific
DNA marker, the relative extent of donor-derived cells was shown to be dense
throughout the graft with some migration of cells into the surrounding striatal
white matter as well as into the corpus callosum of the contralateral hemisphere.
We have previously shown the growth of glial fibers and migration of CD44+
cells in these host white matter tracts (Isacson et al. , 1995), and the present
porcine specific DNA-labelling confirms the migratory capacity of donor glia
within host white matter (Zhou and Lund, 1993).
In contrast, the majority of grafts in the non-Cy A treated rats were small
and contained a sparse distribution of neurons. Interestingly, the glial
component of the graft was relatively preserved whereas the neuronal
component was lost. Cellular infiltrates and perivascular cuffng were often
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present. It is unclear if these non-Cy A treated grafts would persist overtime, yet
the contrast in graft appearance between the two groups indicates the
importance of Cy A treatment on graft survival and the associated functional
recovery. Similar to previous reports, brains in which grafts presumably died
early contained only minor scars along the injection tract whereas a few grafts
showed a small necrotic area with cellular infitration (Brundin et al., 1988b). Of
significance to clinical transplantation, the area of damage was confined to the
graft site and did not extend to the surrounding striatum.
Behavioral evidence of functional grafts as well as long-term neuronal
survival were present in some of the non-CyA treated rats in the present study,
and a moderate degree of prolonged neural xenograft survival in non-
immunosuppressed rats has been reported previously (Bjorklund et al. , 1982;
li(
Brundin et al. , 1985c; Daniloff et al., 1985). However, the fact that the
immunological privilege of the brain is not absolute (Pakzaban and Isacson, 1994;
...
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Widner and Brundin, 1988) necessitates immunosuppression of the host for
xenograft survival. The administration of CyA has been demonstrated to
1!r
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enhance neural xenograft survival (Brundin et al., 1985c; Brundin et al. , 1988b),
presumably due to the inhibition of IL-2 production and subsequent T cell
J.' Hj.
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activation (Bierer et al. , 1993). In addition, recent data show that the
immunosuppressants Cy A and FK506 decrease NMDA-mediated glutamate
toxicity in cortical cultures (Dawson et al., 1993). Yet, neither CyA nor FK506
have been shown to have an effect on neuronal survival in the absence of a toxic
insult in vitro (Dawson et al., 1993). While it is unclear to what degree these
results can accurately be extrapolated to grafted neurons, these trophic effects
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may be synergistic with the well known immunosuppressive effects of Cy A on
graft survival.
Alternatives and adjuncts to Cy A immunosuppression are under
investigation. While steroids and azathioprine are used in some clinical
neurotransplantation protocols (Lindvall et al., 1994; Widner et aI. , 1992), their
precise therapeutic benefit -for neural grafting remains unclear. A single dose of
the anti-inflammatory steroid methylprednisolone (5 mg/kg) was administered
preoperatively in the present study. A recent study in rodents has demonstrated
that 30 mg/kg/ d of methylprednisolone enhances graft survival whereas a lower
dose of 15 mg/kg/ d results in the majority of the grafts being rejected (Duan et
al. 1996). The use of a triple drug regimen comprised of CyA, prednisolone, and
azathioprine has been reported to increase the survival rate of xenografted
hippocampal tissue blocks in rats(Pedersen et al., 1995). Alternatively, it has
been reported that corticosteroid treatment may reduce graft survival (Patino et
aI., 1992). Thus, further studies are necessary to defie clearly the effects of
steroid immunosuppression in CNS grafting. As an alternative to drug
therapies, treatment with antibodies to the interleukin II receptor has been shown
to protect against immune rejection in human-to-rat VM grafting (Honey et aI.
1990). In additon, prior masking of donor MHC Ion transplanted cells enhances
the frequency of neural xenograft survival relative to no immunosuppression in a
rat model of Huntington s disease (Pakzaban et al., 1995). Yet, such masking is
not equivalent to Cy A as graft size was significantly reduced in the masked
group relative to the CyA treated group. We are currently evaluating the effects
of MHC I masking of porcine VM cells as well as other immunomodulatory
techniques on graft survival in the rat Parkinson model.
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Current human fetal transplantation paradigms are restricted by several
practical issues, the foremost of which is limited tissue supply. In agreement
with previous studies (Freeman et aI., 1988; Huffaker et al. , 1989), the present
results demonstrate that transplanted porcine fetal dopaminergic neurons are
able to reinervate, the brain of immunosuppressed adult rats and mediate
functional recovery. Thus, large quantities of age-appropriate DA neurons can
be isolated and transplanted to the host brain where synaptic circuitry can be
established resulting in regulated DA release. This long-term graft survival and
extensive. striatal reinervation demonstrate the potential utilty of transplanting
fetal porcine DA neurons for the treatment of PD.
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CHAPTER VI
GENERAL DISCUSSION
Therapeutic approaches to the treatment of Parkinson s disease
Limitations of current thera ies for Parkinson s disease. Current
therapies for PD are based primarily on the pharmacologic replacement of DA by
the administration of L-dopa. Recently, surgical interventions including
palldotomy and fetal cell transplantation have become more widespread.
However, each of these approaches has limitations as L-dopa therapy is
!II
",;"
associated with debiltating motor abnormalities and decreased efficacy whereas
the long-term clinical outcome from palldotomy is largely unknown, and
;:' 1
transplantation of fetal neurons is associated with practical issues regarding
attainent of sufficient tissue.
f,,
Since PD is characterized primarily by the loss of a single neurotransmitter
system, pharmacological replacement of DA is of signficant clinical benefit.
However, while the development of L-dopa therapy is considered to be
revolutionary in the treatment of PD, disease progression persists, and long-term
treatment is associated with decreased efficacy as well as several adverse effects.
Motor fluctuations associated with long-term L-dopa treatment are thought to be
attributable in part to decreased DA buffering capacity in the brain due to loss of
nerve terminals (Chase et al., 1993). Thus, mere DA replacement is not sufficient
to achieve optimal therapeutic benefit as it is thought that fluctuating brain DA
143
levels contribute to the observed motor abnormalities. The benefits of L-dopa
often decline after approximately 3 years of treatment (Marsden and Parkes
1977; Yahr, 1977). Furthermore, evidence suggests that L-dopa itself may
contribute to disease progression by producing reactive oxygen species which
exacerbate ongoing neurodegenerative processes (Spina and Cohen, 1989). L-
dopa and other dopaminergic agonists clearly improve the quality of life for
parkinsonian patients initially. However, the disease cannot be adequately
managed long-term using available pharmacologic agents, and present therapies
do not halt disease progression.
Surgical approaches for the treatment of PD are aimed either at replacing
striatal DA via transplantation of fetal dopaminergic neurons or interrupting the
circuitry of the basal ganglia by lesioning brain structures. Whileinitial
outcomes from palldotomies are encouraging, it is unclear if the observed
therapeutic benefit wil be sustained. Transplantation of human fetal VM into
the DA depleted striatum of parkinsonian patients has yielded very promising
results thus far. As discussed in Chapter 5 and below, the major constraint
encountered in transplantation is obtaining sufficient tissue for grafting. In
addition, several factors including graft site and placement as well as optimal
number of cells and immunosuppression protocols have not yet been
conclusively determined. Furthermore, as only approximately 10% of grafted
cells survive following implantation, and only 5-10% of these cells are
dopaminergic (Brundin et al., 1985b), development of strategies to enhance
survival of transplanted neurons is of great interest.
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Alternative approaches to the treatment of Parkinson s disease . The
optimal approach to the treatment of neurodegenerative disorders would halt
disease progression by preventing further neuronal death. As presented in
Chapters 2 and 3, NTFs have been shown to protect against neuronal loss in
animal models of nigra I degeneration. Yet, several issues remain to be addressed
before NTF delivery to the adult brain may be realized as a clinical alternative.
Furthermore, the mechanisms underlying NTF protection are largely unknown.
As shown in Chapter 4, NTFs likely act in part by decreasing the formation of
reactive oxygen species. Until neuroprotective therapies are developed, DA
replacement via transplantation of fetal mesencephalic neurons offers significant
hope for PD patients. Since current procedures are limited by practical as well as
ethical issues, we have investigated the use of fetal porcine VM as an alternative
cell source for transplantation in PD. As demonstrated in Chapter 5, xenografts
are able to survive in the immunosuppressed rat brain and mediate fuctional
recovery. However, as discussed below, issues of immunosuppression and
approaches to enhancing neuronal survival deserve further investigation.
Experimental approaches to neuroprotection
of dopaminergic neurons
Neuro rotection in a rat model of Parkinson s disease. Using an MPP+
model of SN degeneration, we have shown that BDNF delivered by genetically
engineered fibroblasts is able to protect against dopaminergic neuronal
degeneration associated with inhibition of mitochondrial complex I (Chapter 2).
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Furthermore, the present results indicate that BDNF is able to increase DA levels
in the SN in this same lesion paradigm (Chapter 3) Demonstration of
neuroprotection by BDNF suggests that this factor may be able to retard or halt
ongoing neurodegenerative processes. Moreover, the augmentation of DA
associated with BDNF delivery suggests that this NTF may also be able to
enhance the function of surviving dopaminergic neurons and increase DA levels
in remaining cells.
The MPP+ model of SN degeneration employed in these studies is useful
for the understanding of the potential therapeutic role of NTs. MPTP
administration causes a parkinsonian syndrome in humans as a result of
inhibiton of complex I of the mitochondrial electron transport chain by its active
metabolite MPP+ (Langston et al., 1983). Evidence for impaired complex I
activity has been found in PD patients (e.g., Parker et al. , 1989; Schapira et al.
1990; Schapira et al., 1989; Shoffner et al., 1991) suggesting that the neuronal
death induced by MPP+ may accurately model the neurodegenerative processes
underlying PD. Demonstration of effective neuroprotection in the MPP+
paradigm may therefore have direct relevance to the pathogenesis and treatment
of PD. It has been suggested that neurodegenerative diseases may be associated
with trophic factor deficiency (Appel, 1981; Hefti, 1983). While no mutation in
the BDNF gene has been identified in cases of autosomal parkisonism (Gasser et
al., 1994), it remains possible that levels are deficient or that receptor interactions
may be altered in the parkinsonian brain. Similar to the trophic factor
dependence observed for developing neurons, adult neurons also may be
dependent on trophic support, and lack of such a factor may result in impaired
cellular function culminating in neuronal death.
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In the studies presented in Chapters 2 and 3, the observed neuroprotective
effects are mediated by a BDNF dose which is substantially lower than the dose
employed in many infusion studies (e.g., Altar et aI., 1992; Martin-Iverson et aI.
1994; Sauer et al., 1993). This observation suggests that there may be a dose-
response curve for BDNF efficacy. Furthermore, it is possible that the delivery
via cells is more effective due to combined effects with baseline levels of other
NTFs secreted by the fibroblasts. Unfortunately, the MPP+ model precludes
behavioral testing of the effects of BDNF as a large striatal lesion is produced
following infusion of this toxin. It would be of interest to determine not only the
behavioral effects of BDNF but also the striatal neurochemical parameters
associated with cell mediated BDNF delivery. It has recently been reported that
GDNF delivered intraventricularly to primates lesioned unilaterally with MPTP
is associated with remarkable behavioral improvement (Gash et al., 1996).
Interestingly, while these behavioral signs were accompanied by increased DA
levels in the SN, VTA and palldum, DA levels in the caudate and putamen were
not restored. Further characterization of the neurochemical and behavioral
properties of trophic factors as well as the associated cellular and receptor
alterations are necessary to fully address the clinical implications of the observed
effects.
In addition to the findings presented in Chapters 2 and 3, studies have
demonstrated that infusions of BDNF protect against the cell death associated
with axotomy (Hagg, 1994), and BDNF-secreting fibroblasts have been shown to
protect against neuronal degeneration associated with striatal injection of 6-
OHDA (Levivier et al., 1995). While the induction of cell death differs in these
paradigms, these findings confirm that BDNF is neuroprotective in vivo. The
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mechanism of neuroprotection by BDNF has not yet been elucidated. 
discussed previously, neuronal death may occur as a result of various cellular
insults culminating in the activation of cellular proteases and the production of
free radicals. As discussed below, it is thus possible that BDNF as well as other
NTFs protect againt cellular damage by up regulating the activity of protedive
mechanisms. Indeed, BDNF has been shown to increase levels of the antioxidant
glutathione reductase in vitro (Spina et al., 1992).
In addition to BDNF, several other NTFs have been shown to be trophic
for dopaminergic neurons. As many of these factors are members of different
gene familes and act via different receptors, it is likely that they may induce
different cellular responses. Thus, combined treatment with more than a single
factor may produce additive or synergistic effects. Indeed, in the wobblermouse
':11
model of motor neuron disease, the combined administration of BDNF and
CNTF provided significantly greater protection againt neuronal loss than either
factor alone (Mitsumoto et aI. , 1994).
I '
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PD is well-suited for neuroprotective therapy as primarily one cell
population is affected and the clinical manifestations are not apparent until 80- I".I""
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85% of SN dopaminergic cells have degenerated and striatal DA levels are
depleted by 80% (Marsden, 1982a). PET scan studies have demonstrated that
nigra I cell loss can be detected during the preclinical stages of PD (Brooks, 1991;
Burn et al., 1992). Thus, identification of patients during the subclinical stage in
combination with neuroprotective therapies could theoretically enable the
prevention of disease progression. At present, however, PET scans are not
widely available. Moreover, further characterization of NTFs is necessary before
clinical applications are feasible. To date, no clear preventative benefit has been
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reported in clinical trials of NTFs, and high doses have been associated with
significant toxicity (Miler et aI., 1996). As discussed below, several factors must
be evaluated in order to consider the therapeutic applications of NTFs.
Mechanism of neuro rotection in a rat model of mitochondrial
airment. The mechanism underlying the BDNF-mediated neuroprotection in
the MPP+ model is not yet known. In order to investigate the mechanism of
NTF-mediated neuroprotection, we studied the effects of NGF in a 3-NP model
of striatal degeneration. 3- like MPP+, is a mitochondrial toxin. By inhibiting
complex II of the electron transport chain, 3-NP produces striatal cell loss. The
use of this model for the mechanistic evaluation of NTF-mediated
neuroprotection is advantageous as more tissue (striatum versus SN) is available
for analysis. While the MPP+ and 3-NP models differ in their neuropathology,
':I'
both act via mitochondrial blockade. The use of the paradigm presented in
Chapter 4 has enabled us to evaluate NTF protective mechanisms in vivo.
' ':
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However, the differences in the MPP+ and 3-NP models as well as the trophic
factors evaluated clearly distinguish the paradigms. Subsequent studies wil be
I ,
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focused on similar evaluation in the MPP+ model
, likely using tissue pooled
from treatment groups.
As demonstrated in Chapter 4, NGF is able to attenuate the production of
3-nitrotyrosine in vivo. 3-nitrotyrosine is the product of peroxynitrite-mediated
tyrosine nitration and thus serves as an indirect measure of peroxynitrite activity.
The observed reduction in 3-NP induced generation of 3-nitrotyrosine in the
NGF treated group suggests that NGF acts in part by reducing peroxynitrite
formation. Thus, NGF may increase SOD or decrease NO levels, thereby
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decreasing peroxynitrite. These findings not only demonstrate one mechanism
by which NGF is able to protect against 3-NP toxicity, but also suggest that
therapeutic agents targeting NOS iribition or enhancing SOD levels may be
able to protect against oxidative stress in neurodegeneration.
Similar to 3-NP, MPTP has also been reported to increase the generation of
3-nitrotyrosine in vivo (Schulz et al., 1995b). Furthermore, treatment with the
neuronal nitric oxide synthase inhibitor 7-nitroindazole was shown to protect
against the MPTP-induced reduction in DAas well as the increase in 
nitrotyrosine suggesting that NO and peroxynitrite are important mediators of
MPTP toxicity. Thus, BDNF protection against MPP+ toxicity may also involve
decreased formation of peroxynitrite.
Considerations for clinical use of neurotro hic factors. The trophic
support and neuroprotection afforded by NTFs indicate the possible therapeutic
applicabilty of these factors to neurodegenerative disorders (Hefti, 1994; Jelsma
and Aguayo, 1994; Lindsay et al., 1993). However, the clinical application of
NTFs as a therapeutic modality for neurodegenerative disorders requires an
effective means of delivery. As NTFs cannot cross the BBB, alternate strategies
for delivery to the CNS must be considered.
Various approaches to circumventing the BBB have been investigated.
Direct intraparenchymal or intraventricular insions have been employed in
numerous experimental paradigms. While this method of delivery allows for
dosage control and site-specificity, there is often parenchymal damage at the
cannula placement site. Also, the delivery efficiency of factors may be limited by
diffusion properties of the factor within brain parenchyma (Morse et al., 1993).
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Additionally, intraventricular administration of the TrkB ligand BDNF is
ineffective due to binding by truncated TrkB receptors which are present in the
ependymal lining of the ventricles (Kordower et al., 1994b). Similar difficulties
may be expected for NT-4/5 as this factor also binds to the TrkB receptor.
Continuous delivery could be achieved by a pump reservoir connected to a
cannula. However, growth factor stabilty in the reservoir may be of concern.
Moreover, approaches involving intracerebral cannulae introduce a high risk for
infection. An additional approach to delivery would be to modify the NTF in
order to enable BBB passage. It has been shown that NGF-transferrin receptor
antibody conjugates are able to cross the BBB and protect neurons from
excitotoxic lesions suggesting that such an approach may provide a non-invasive
route of delivery to the brain (Friden et aI. , 1993; Kordower et al., 1994a).
As an alternative to direct infusion, methods for cell-mediated delivery of
therapeutic proteins have been developed including ex vivo as well as in vivo
gene transfer. Ex vivo gene transfer involves the genetic engineering of cells to
express a transgene prior to transplantation (see Gage et al. , 1987 for review).
Intracerebral graftg of primary or immortalized fibroblasts genetically
engineered to release trophic factors allows for site specific biological delivery
which has been shown to prevent cell loss in a variety of in vivo lesion paradigms
(e.g., Kawaja et aI., 1992; Rosenberg et aI., 1988; Schumacher et aI., 1991). In
contrast to the use of immortalized fibroblast lines, the use of primary fibroblasts
decreases the likelihood of tumor formation following implantation and would
allow for harvesting cells from the affected individual, thereby eliminating the
possibilty of immune rejection. Alternatively, cell division of immortalized
fibroblasts could be arrested prior to implantation or cells could be encapsulated
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in a semipermeable membrane (Winn et al., 1994). Difficulties with achieving
stable, long-term gene expression by genetically modified cells remain an
obstacle to this approach as gene expression is down-regulated post-implantation
(Palmer et aI., 1991). Improved vector constructs with alternate promoters may
resolve this issue. Moreover, the use of inducible promoters (Gossen and Bujard
1992) may allow for regulated factor delivery by the genetically modified cells.
Virus vectors have also been used to infect human neural progenitors prior to
transplantation (Martinez-Serrano et al. , 1995; Sabate et al., 1995) suggesting the
potential utilty of ex vivo genetic engineering of progenitor cells.
Several groups have attempted to infect cells in vivo via herpes simplex
virus (Breakefield and DeLuca, 1991), adenovirus (Horellou et al., 1994; Le Gal La
Salle et al., 1993), or adeno-associated virus (Kaplitt et al., 1994) vectors. While
these approaches of genetic modification of cells in vivo holds promise for future
therapeutic interventions, current methodologies are constrained by limited gene
expression as well as by the cytopathogenicity and the low rate of infectivity
associated with virus vectors.
Optimal methods of delivery may vary for NTFs due to receptor
distribution and factor properties. Moreover, for each growth factor, effective
dose ranges need to be determined as the dose-response relationship for many
factors indicates higher doses may be less effective. Indeed, such a dose-
response effect has been reported in vitro for the trophic effects of NT -3 and NT-
4/5 on DA neurons (Hyman et al., 1994), and studies ofaxotomized SN neurons
as well as axotomized motor neuron rescue demonstrate a submaximal response
with higher doses of BDNF (Hagg, 1994; Vejsada et al., 1994). As suggested by
Vejsada, et al. (1994), high levels of ligand may result in decreased affinity or
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down-regulation of the high affinity TrkB receptor or an upregulation of the
inactive truncated TrkB receptor, thereby accounting for the decreased efficacy of
higher doses of BDNF.
Expe;rimentalapproaches to neurotransplantation
of dopaminergic neurons
Trans lantation of fetal orcine do aminer ic neurons. The primary
limitations to neuronal grafting are the limited supply of tissue and the low yield
of surviving dopaminergic neurons. In order to investigate the use of alternate
cell sources for transplantation in PD, we have investigated the survival and
function of fetal porcine VM neuroblasts grafted in the 6-0HDA rat model of PD.
As demonstrated in Chapter 5, following transplantation of porcine
dopaminergic neurons to the denervated striatum, Cy A treated rats exhibited
sustained functional recovery, as measured by a reduction in amphetamine
induced rotation, whereas non-Cy A treated rats showed only a transient decline
in rotation. The degree of rotational recovery was found to correlate with the
number of surviving TH neurons in the grafts, and it was determined that a
survival of approximately 80-100 TH + neurons was necessary to achieve a 50%
reduction in net rotational asymmetry. Remarkably, near complete graft-derived
striatal reinervation was observed in the Cy A treated rats. These fidings
suggest that fetal porcine neuroblasts may provide an alternate source of
dopaminergic neurons for transplantation in PD.
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Properties of fetal porcine grafts Histological analysis of the porcine
grafts revealed extensive reinervation of the striatum ipsilateral to the lesion.
Similar to human-to-rat grafting studies (Wictorin et aI. , 1992), additional
histological evaluation of the porcine xenografts has revealed target-specific long
distance axonal growth by the transplanted neuroblasts (Isacson et aI., 1995).
Thus, despite species differences, the grafted cells are able to reconstruct
neuronal circuitry and mediate functional recovery in the immunosuppressed
adult brain.
While grafted dopaminergic neurons are able to compensate for many
lesion-induced deficits, this req)Very is incomplete as, for example, complex limb
use measured by paw reaching abilty as well as the adipsia and aphagia induced
by bilateral lesions are not improved by rat-to-rat grafting (Bjorklund et al.
1980a; Dunnett et al., 1981b; Dunnett et aI. , 1987). Several factors have been
suggested to underlie this lack of recovery, including insufficient striatal
reinervation, incomplete integration with the host circuitry, as well as failure to
reinervate non-striatal target areas (see Bjorklund, 1992 for review). It has,
however, been shown the more extensive reinervation and integration
produced by micrografting of fetal neurons results in recovery on the paw
reaching task (Nikkhah et al. , 1994; Nikkhah et al., 1993a). As the porcine grafts
in the present study demonstrated such remarkable fiber outgrowth and near
complete striatal inervation, it would be of interest to determine if these grafts
are also able to compensate for lesion induced paw reaching deficits.
Neurochemical analyses of fetal rat grafts have demonstrated that only 3%
of normal DA levels are necessary for rotational recovery. Striatal DA levels are
restored by approximately 13% following macro grafting and by 30% using
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micro grafting techniques (Nikkhah et al., 1994). Analysis of DA levels in the
porcine grafts would be useful to evaluate the comparative efficacy of fetal
porcine dopaminergic neurons relative to the micrografting or macrografting of
fetal rat tissue. The finding that only 80-100 porcine neurons are necessary to
achieve rotational recovery whereas 100-200 rats neurons are needed (Brundin et
al. , 1985b) suggests that the porcine cells may provide more DA.
Xenotrans lantation and immuno rotective strate ies. While the
porcine xenografts were able to survive and attenuate rotational deficits in 6-
OHDA lesioned rats, the rate of graft survival in the CyA treated rats was only
55%. This observation suggests that in addition to cell-mediated responses
which are inhibited by Cy A, other immunological factors may be involved. 
has been suggested that humoral immunity may be important in xenograft
rejection by activating complement and promoting antibody-dependent cellular
cytotoxicity. However, determination of the role of antibodies in neural
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xenograft rejection awaits detailed characterization. The observed 55% survival
rate is in agreement with the finding that the immunoprotection afforded by Cy 
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is often incomplete (Pakzaban and Isacson, 1994) and indicates the importance of
developing alternate immunosuppression strategies.
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The 6-0HDA model allows for indirect monitoring of graft survival via
rotational testing during graft growth and maturation. However
, the onset of
behavioral recovery following transplantation of porcine neurons does not occur
until approximately 9 weeks after grafting. Thus, if a graft is rejected late after
transplantation, the loss of neuronal function may be detected. However, there is
no indicator of graft health prior to the onset of behavioral recovery, and,
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characterization of immunological reactions at the precise time of rejection may
not be possible if the graft is rejected early.
As mentioned previously, triple drug therapy (Pedersen et al.
, 1995) as
well as methylprednisolone alone (Duan et at , 1996) have been shown 
effectively prevent mouse to rat xenograft rejection. It is of interest to determine
the optimal immunosuppression regimen for xenografting to the CNS, and
further evaluation is warranted. In addition to the conventional
pharmacotherapies, novel immunosuppressive strategies directed at various
points in the immune response are under investigation. As discussed previously,
thecytokine IL- , which is secreted by T helper cells, is important in the
regulation of immune responses. By administering an antibody to the IL-
receptor, IL-2 is prevented from binding to its receptor and mediating rejection.
Ten day administration of IL-2 receptor antibody to rats receiving'
intraventricular solid allografts has been demonstrated to significantly increase
graft survival and attenuate the cellular infiltrate and MHC up regulation
observed in control allografted rats (Wood et al. , 1992). Moreover, such
treatment has been shown to effectively. prevent xenograft rejection of human to
rat transplants (Honey et al. , 1990). . Allograft rejection has also been shown to be
prevented by immunoselecting and transplanting neuronal precursors which do
not express MHC antigens (Bartlett et al., 1990). Masking of donor MHC Ion
cells prior to grafting has also been shown to be immunoprotective (Pakzaban et
, 1995). Yet, the graft volume in the masked group was found to be smaller
than that in the CyA treated group. Experiments depleting either CD4 (T helper)
or CD8 (cytotoxic) T cells in allografts or concordant neural xenografts have
demonstrated that CD4 cells are critical mediators of graft rejection and that
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xenograft rejection cannot be mediated by CD8 cells alone (Nicholas et al., 1990;
Wood et al., 1996). Grafts in CD4 T cell depleted hosts were found to survive
significantly longer relative to untreated or CD8 depleted hosts. The combined
depletion of CD4 and CD8 cells resulted in greater graft survival, demonstrating
that CD8 cells are indeed involved in the rejection process. Similar, yet less
dramatic, immunoprotection by CD4 cell depletion was also observed in
discordant neural xenografts (Wood et aI. , 1996).
Such manipulations of the immune system and of transplanted tissue,
either alone or in conjunction with currently used immunosuppressive drugs,
may provide enhanced immunoprotection. Further evaluation and
characterization of the xenograft rejection process by analysis of cellular
infiltrates and cytokine profies within the graft wil likely facilitate the
development of additional strategies to prevent xenograft rejection.
Strate ies to increase neuronal survival. As addressed in Chapter 5, a
major constraint to fetal transplantation is the limited supply of tissue. Long- J"'
term storage of tissue prior to transplantation is associated with reduced
neuronal survival and at present is thus not a suitable technique. In addition to
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using cells from a xenogeneic source, a further approach to circumventig the
current graftig limitations is to enhance the yield of surviving dopaminergic
neurons presently achieved by standard cell suspension graftig. Approximately
10% of the neurons in the VM are dopaminergic. However, it is estimated that
only 10% of the grafted neurons survive, thereby requiring up to 10-15 fetal VMs
to adequately reinervate the parkinsonian striatum (Bjorklund, 1993).
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As described, NTFs are able to promote the survival of dopaminergic
neurons in vitro. In addition, some NTFs have been demonstrated to have effects
on grafted fetal VM cells. For example, BDNF infusions to VM grafted rats have
been shown to enhance striatal innervation (Yurek et al. ' 1996). In addition
bFGF infusions (Mayer et al. , 1993b) or co-grafting of bFGF transfected
fibroblasts (Takayama et al. , 1995) have been shown to increase both survival and
fiber outgrowth of transplanted DA neurons. GDNF has been shown to increase
TH neuronal survival of in oculo grafts of fetal VM, suggesting that GDNF also
may be able to enhance the survival of neurons grafted within the brain
(Stromberg et al. , 1993). As other factors have been shown to be trophic for
dopaminergic neurons, investigation of additional co-grafting combinations are
of interest. Moreover, characterization of the trophic mechanisms may indicate
the underlying cause of the low survival rate.
The cause of the neuronal attrition is thought to be a result of oxidative
stress associated with cell preparation and transplantation, and several studies
support this hypothesis. Lazaroidsare aminosteroids which inibit the
generation of free radicals and lipid peroxidation. Treatment of fetal VM cell
cultures with lazaroids has been found to increase the survival of TH + neurons
(Frodl et aI. , 1994b). Moreover lazaroid treatment of VM cells has been
demonstrated to significantly increase cell viabilty prior to grafting and increase
TH+ neuronal survival following transplantation by a factor of 2.6 (Nakao et al.
1994). Further evidence for the involvement of oxidative stress in the low
survival rate of grafted dopaminergic neurons is provided by studies in which
donor neurons were obtained from transgenic mice overexpressing SOD (Nakao
et al., 1995). Similar to the survival effect observed in the lazaroid experiments,
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grafting of tissue derived from the SOD transgenics resulted in improved cell
viabilty and a 4-fold increase in TH + neuronal survival. These results support
the theory that the low yield of TH+ neurons is due at least in part to oxidative
stress. Thus, administration of lazaroids or other antioxidative agents may be
expected to improve the yield of surviving DA neurons in clinical transplantation
as well.
Considerations in clinical neurotrans lantation. While
neurotransplantation of fetal dopaminergic neurons holds promise for the
treatment of PD, parkinsonian symptoms are not completely alleviated by
grafting (see Lindvall, 1991 for review). Similar to the observations from animal
studies, the incomplete recovery is thought to be attributable to insufficient
reinervation, incomplete reciprocal connections with the host due to ectopic
graft location, as well as a failure to compensate for the non-dopaminergic
components of PD. In addition to the aforementioned limited survival and 8';'
immunological issues, additional factors are relevant to clinical transplantation.
Unlike the toxic inults which acutely produce animal models, PD is a
I!,'
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progressive disorder of nigral degeneration. It is therefore possible that ongoing
disease progression could affect the grafted neurons (Lindvall, 1991). However
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long-term graft survival with improved fluorodopa uptake has been observed
suggesting that the grafted neurons are not affected (Lindvall 
et aI., 1994). In
addition, patients receiving fetal grafts remain on L-dopa therapy. As L-dopa
has been suggested to be toxic for dopaminergic neurons, there has been a
theoretical concern that continued L-dopa therapy may negatively impact the
grafted neurons. However, evaluation of rats receiving transplants and chronic
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dopa/ carbidopa treatment have failed to demonstrate any detrimental effect of
dopa on graft function (Blunt et aI. , 1991a) or TH neuron survival and
outgrowth (Blunt et al. , 1991b).
The development of strategies to improve cell survival and the further
refinement of grafting techniques and optimization of graft placement wil likely
improve the clinical outcome of PD patients receiving VM grafts.
Conclusions
Accumulatig evidence indicates the involvement of oxidative stress and
excitotoxicity in the pathogenesis of neurodegenerative disorders such as PD. As
primarily one neuronal population is affected in PD, therapeutic approaches
directed at protection of dopaminergic neurons may prevent disease progression
and the onset of clinical symptoms. However, if cell death cannot be prevented
neuronal replacement and reconstruction of synaptic circuitry via the
transplantation of fetal DA neurons is indeed possible.
NTFs are able to protect against cellular insults suggesting their potential
clinical applicabilty. The pathway to neuronal death involves several
mechanisms, including increased intracellular calcium and the generation of free
radicals. Thus, NTF intervention at single or multiple sites in this process may
protect against cellular insults and degenerative processes. By preventing the
formation of oxidative radicals and/ or enhancing radical scavenging capacities,
NTFs may prevent neuronal damage.
160
The various mechanisms for protection coupled with the multiple sites for
possible intervention suggest that NTFs acting via different cellular mechanisms
or at sequential sites in these neurodegenerative pathways may provide additive
or synergistic protective effects. While the precise mechanisms of NTF-mediated
neuroprotection are not fully characterized, the trophic and protective effects of
NTFs indicate their promise for future therapeutic application. However, the
clinical utilty of NTs is presently limited by delivery and dosage issues.
Strategies to circumvent the BBB need to be refined as systemic delivery of NTFs
may be associated with untoward effects via actions on additional cell
populations. Furthermore, the overlap in NTF specificity indicates that the
delivered factor is likely to affect more than the target neuronal population. The
evaluation of dose-response relationships and long-term effects of NTF treatment
wil aid in the development of NTFs as a therapeutic approach for the treatment
of neurodegenerative disorders. III
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, Presently, there are no neuroprotective therapies available for the
treatment of PD. While current pharmacological therapies are limited by tii.'UlfOl
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significant side effects, neurotransplantation of fetal dopaminergic cells provides
a therapeutic alternative for PD. Extensive studies in rodents have demonstrated
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that grafted dopaminergic neurons can reinnervate the DA depleted striatum
mediate fuctional recovery, restore DA levels, and form synaptic connections
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with host neuronal circuitry. Importantly, grafted DA neurons exhibit regulatory
capacities. The regulatory capacity and graft-host integration demonstrate the
advantages of transplanted neurons compared to genetically engineered cells,
which do not possess this abilty. The long-term graft survival and fuctional
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improvement observed in transplanted parkinsonian patients demonstrate the
efficacy of this treatment approach.
The optimal treatment of neurodegenerative disorders would prevent
ongoing neuronal death and halt disease progression. The present results
support the idea that NTFs may be able to prevent ongoing neurodegenerative
processes, perhaps by decreasing oxidative stress. While NTFs may provide
such protection, further characterization of these factors is necessary prior to
achieving clinical utility. While neuroprotective therapies remain experimental
reconstruction of neuronal circuitry may be achieved via neurotransplantation of
fetal dopaminergic neurons. Current transplantation approaches are constrained
in part by the limited supply of tissue. Yet, the continued refinement of
methodologies as well as the development of alternate cell sources and strategies
to improve cell survival wil likely result in the greater accessibilty of
neurotransplantation as a treatment for PD.
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